Patent Grant
11246913
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ACSII copy, created on Jun. 13, 2019, is named txt 611562 102487-036CON4.txt and is 1,448 bytes in size.
The present invention relates to organic chemistry, formulation chemistry, and peptide chemistry applied to pharmaceutical research and development. Aspects of the present invention provide suspension formulations of insulinotropic peptides for use in mammals and for the treatment of diseases or conditions.
Glucagon-like peptide-1 (GLP-1) is ‘important hormone and a fragment of the human proglucagon molecule. GLP-1 is rapidly metabolized by a peptidase (dipeptidylpeptidase IV or DPP-IV). A fragment of GLP-1, glucagon-like peptide-1 (7-36) amide (glucagon-like insulinotropic peptide, or GLIP) is a gastrointestinal peptide that potentiates the release of insulin in physiologic concentrations (Gutniak M., et al., N Engl J Med. 1992 May 14; 326(20):1316-22). GLP-1 and GLP-1(7-36)amide are incretins. Incretins are gastrointestinal hormones that cause an increase in the amount of insulin released from beta cells after eating.
Food intake, as well as stimulation of the sympathetic nervous system, stimulates secretion of GLP-1 in the small intestine of mammals. Further, GLP-1 stimulates the production and secretion of insulin, the release of somatostatin, glucose utilization by increasing insulin sensitivity, and, in animal studies, also stimulates beta-cell function and proliferation.
GLP-1(7-36)amide and GLP-1(7-37) normalize fasting hyperglycemia in Type 2 diabetic patients (Nauck, M. A., et al., Diabet. Med. 15(11):937-45(1998)). Exendin-4 is an incretin mimetic (i.e., it mimics physiological effects of incretins) purified from Heloderma suspectum venom (Eng, J., et al., J. Biol. Chem. 267:7402-05 (1992)) and shows structural relationship to the incretin hormone GLP-1(7-36)amide. Exendin-4 and truncated exendin-(9-39)amide specifically interact with the GLP-1 receptor on insulinoma-derived cells and on lung membranes (Goke R, et al., J Biol. Chem. 268:19650-55 (1993)). Exendin-4 has approximately 53% homology to human GLP-1 (Pohl, M., et al., J Biol. Chem. 273:9778-84 (1998)). Unlike GLP-1, however, exendin-4 is resistant to degradation by DPP-IV. A glycine substitution confers resistance to degradation by DPP-IV (Young, A. A., et al., Diabetes 48(5):1026-34(1999)).
The present invention relates to suspension formulations comprising a particle formulation and a suspension vehicle, as well as devices comprising such formulations, methods of making such formulations and devices, and methods of use thereof.
In one aspect, the present invention relates to a suspension formulation comprising, a particle formulation comprising an insulinotropic peptide and one or more stabilizer selected from the group consisting of carbohydrates, antioxidants, amino acids, buffers, and inorganic compounds. The suspension formulation further comprises a non-aqueous, single-phase suspension vehicle comprising one or more polymer and one or more solvent. The suspension vehicle exhibits viscous fluid characteristics and the particle formulation is dispersed in the vehicle.
In one embodiment, the suspension formulation comprises a particle formulation comprising an insulinotropic peptide, a disaccharide (e.g., sucrose), methionine, and a buffer (e.g., citrate), and a non-aqueous, single-phase suspension vehicle comprising one or more pyrrolidone polymer (e.g., polyvinylpyrollidone) and one or more solvent (e.g., lauryl lactate, lauryl alcohol, benzyl benzoate, or mixtures thereof.
Examples of insulinotropic peptides include, but are not limited to, glucagon-like peptide-1 (GLP-1), exenatide, and derivatives or analogues thereof. In one embodiment of the invention, the insulinotropic peptide is GLP-1(7-36)amide. In another embodiment of the invention, the insulinotropic peptide is exenatide.
The particle formulations of the present invention may further comprise a buffer, for example, selected from the group consisting of citrate, histidine, succinate, and mixtures thereof.
The particle formulations of the present invention may further comprise an inorganic compound, for example, selected from the group consisting of citrate, histidine, succinate, and mixtures thereof NaCl, Na2SO4, NaHCO3, KCl, KH2PO4, CaCl2, and MgCl2.
The one or more stabilizer in the particle formulations may comprise, for example, a carbohydrate selected from the group consisting of lactose, sucrose, trehalose, mannitol, cellobiose, and mixtures thereof.
The one or more stabilizer in the particle formulations may comprise, for example, an antioxidant selected from the group consisting of methionine, ascorbic acid, sodium thiosulfate, ethylenediaminetetraacetic acid (EDTA), citric acid, cysteins, thioglycerol, thioglycolic acid, thiosorbitol, butylated hydroxanisol, butylated hydroxyl toluene, and propyl gallate, and mixtures thereof.
The one or more stabilizer in the particle formulations may comprise an amino acid.
In one embodiment, the solvent of the suspension vehicle of the present invention is selected from the group consisting of lauryl lactate, lauryl alcohol, benzyl benzoate, and mixtures thereof. An example of a polymer that can be to formulate the suspension vehicle is a pyrrolidone (e.g., polyvinylpyrrolidone). In a preferred embodiment, the polymer is a pyrrolidone and the solvent is benzyl benzoate.
The suspension formulation typically has an overall moisture content less than about 10 wt % and in a preferred embodiment less than about 5 wt %.
An implantable drug delivery device may be used to contain and deliver the suspension formulation of the present invention. In one embodiment the device is an osmotic delivery device.
The suspension formulations of the present invention can be used to treat any of a number of disease states or conditions in a subject in need of treatment, for example, type II diabetes. In one embodiment, an implantable drug delivery device delivers a suspension formulation of the present invention at a substantially uniform rate for a period of about one month to about a year. The device may, for example, be implanted subcutaneously in a convenient location.
The present invention also includes methods of manufacturing the suspension formulations, particle formulations, suspension vehicles, and devices of the present invention as described herein.
These and other embodiments of the present invention will readily occur to those of ordinary skill in the art in view of the disclosure herein.
All patents, publications, and patent applications cited in this specification are herein incorporated by reference as if each individual patent, publication, or patent application was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. As used in this specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a solvent” includes a combination of two or more such solvents, reference to “a peptide” includes one or more peptides, mixtures of peptides, and the like.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although other methods and materials similar, or equivalent, to those described herein can be used in the practice of the present invention, the preferred materials and methods are described herein.
In describing and claiming the present invention, the following terminology will be used in accordance with the definitions set out below.
The terms “peptide,” “polypeptide,” and “protein” are used interchangeable herein and typically refer to a molecule comprising a chain of two or more amino acids (e.g., most typically L-amino acids, but also including, e.g., D-amino acids, modified amino acids, amino acid analogues, and/or amino acid mimetic). Peptides may also comprise additional groups modifying the amino acid chain, for example, functional groups added via post-translational modification. Examples of post-translation modifications include, but are not limited to, acetylation, alkylation (including, methylation), biotinylation, glutamylation, glycylation, glycosylation, isoprenylation, lipoylation, phosphopantetheinylation, phosphorylation, selenation, and C-terminal amidation. The term peptide also includes peptides comprising modifications of the amino terminus and/or the carboxy terminus. Modifications of the terminal amino group include, but are not limited to, des-amino, N-lower alkyl, N-di-lower alkyl, and N-acyl modifications. Modifications of the terminal carboxy group include, but are not limited to, amide, lower alkyl amide, dialkyl amide, and lower alkyl ester modifications (e.g., wherein lower alkyl is C1-C4 alkyl).
The terminal amino acid at one end of the peptide chain typically has a free amino group (i.e., the amino terminus). The terminal amino acid at the other end of the chain typically has a free carboxyl group (i.e., the carboxy terminus). Typically, the amino acids making up a peptide are numbered in order, starting at the amino terminus and increasing in the direction of the carboxy terminus of the peptide.
The phrase “amino acid residue” as used herein refers to an amino acid that is incorporated into a peptide by an amide bond or an amide bond mimetic.
The term “insulinotropic” as used herein refers to the ability of a compound, e.g., a peptide, to stimulate or affect the production and/or activity of insulin (e.g., an insulinotropic hormone). Such compounds typically stimulate the secretion or biosynthesis of insulin in a subject.
The phrase “insulinotropic peptide” as used herein includes, but is not limited to, glucagon-like peptide 1 (GLP-1), as well as derivatives and analogues thereof, and exenatide, as well as derivatives and analogues thereof.
The term “vehicle” as used herein refers to a medium used to carry a compound. Vehicles of the present invention typically comprise components such as polymers and solvents. The suspension vehicles of the present invention typically comprise solvents and polymers that are used to prepare suspension formulations of polypeptide particles.
The phrase “phase separation” as used herein refers to the formation of multiple phases (e.g., liquid or gel phases) in the suspension vehicle, such as when the suspension vehicle contacts the aqueous environment. In some embodiments of the present invention, the suspension vehicle is formulated to exhibit phase separation upon contact with an aqueous environment having less than approximately 10% water.
The phrase “single-phase” as used herein refers to a solid, semisolid, or liquid homogeneous system that is physically and chemically uniform throughout.
The term “dispersed” as used herein refers to dissolving, dispersing, suspending, or otherwise distributing a compound, for example, a peptide, in a suspension vehicle.
The phrase “chemically stable” as used herein refers to formation in a formulation of an acceptable percentage of degradation products produced over a defined period of time by chemical pathways, such as deamidation (usually by hydrolysis), aggregation, or oxidation.
The phrase “physically stable” as used herein refers to formation in a formulation of an acceptable percentage of aggregates (e.g., dimers and other higher molecular weight products). Further, a physically stable formulation does not change its physical state as, for example, from liquid to solid, or from amorphous to crystal form.
The term “viscosity” as used herein typically refers to a value determined from the ratio of shear stress to shear rate (see, e.g., Considine, D. M. & Considine, G. D., Encyclopedia of Chemistry, 4th Edition, Van Nostrand, Reinhold, N Y, 1984) essentially as follows:
F/A=μ*V/L (Equation 1)
where F/A=shear stress (force per unit area),
μ=a proportionality constant (viscosity), and
V/L=the velocity per layer thickness (shear rate).
From this relationship, the ratio of shear stress to shear rate defines viscosity. Measurements of shear stress and shear rate are typically determined using parallel plate rheometery performed under selected conditions (for example, a temperature of about 37° C.). Other methods for the determination of viscosity include, measurement of a kinematic viscosity using a viscometers, for example, a Cannon-Fenske viscometer, a Ubbelohde viscometer for the Cannon-Fenske opaque solution, or a Ostwald viscometer. Generally, suspension vehicles of the present invention have a viscosity sufficient to prevent a particle formulation suspended therein from settling during storage and use in a method of delivery, for example, in an implantable, drug delivery device.
The term “non-aqueous” as used herein refers to an overall moisture content, for example, of a suspension formulation, typically of less than or equal to about 10 wt %, preferably less than or equal to about 5 wt %, and more preferably less than about 4 wt %.
The term “subject” as used herein refers to any member of the subphylum chordata, including, without limitation, humans and other primates, including non-human primates such as rhesus macaque, chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like. The term does not denote a particular age. Thus, both adult and newborn individuals are intended to be covered.
The terms “drug,” “therapeutic agent”, and “beneficial agent” are used interchangeably to refer to any therapeutically active substance that is delivered to a subject to produce a desired beneficial effect. In one embodiment of the present invention, the drug is an insulinotropic peptide, e.g., GLP-1, exenatide, and derivatives or analogues thereof. The devices and methods of the present invention are well suited for the delivery of polypeptides as well as small molecules and combinations thereof.
The term “osmotic delivery device” as used herein typically refers to a device used for delivery of one or more beneficial agent (e.g., an insulinotropic peptide) to a subject, wherein the device comprises, for example, a reservoir (made, for example, from a titanium alloy) having a lumen that contains a suspension formulation (e.g., comprising an insulinotropic peptide) and an osmotic agent formulation. A piston assembly positioned in the lumen isolates the suspension formulation from the osmotic agent formulation. A semi-permeable membrane positioned at a first distal end of the reservoir adjacent the osmotic agent formulation, as well as a flow modulator (which defines a delivery orifice through which the suspension formulation exits the device) that is positioned at a second distal end of the reservoir adjacent the suspension formulation. Typically, the osmotic delivery device is implanted within the subject, for example, subcutaneously (e.g., in the inside, outside, or back of the upper arm; or in the abdominal area).
Before describing the present invention in detail, it is to be understood that this invention is not limited to particular types of drug delivery, particular types of drug delivery devices, particular sources of peptides, particular solvents, particular polymers, and the like, as use of such particulars may be selected in view of the teachings of the present specification. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting.
In one aspect, the present invention relates to a suspension formulation, comprising a particle formulation and a suspension vehicle. The particle formulation includes, but is not limited to, an insulinotropic peptide and one or more stabilizer. The one or more stabilizer is typically selected from the group consisting of carbohydrates, antioxidants, amino acids, and buffers. The suspension vehicle is typically a non-aqueous, single-phase suspension vehicle comprising one or more polymer and one or more solvent. The suspension vehicle exhibits viscous fluid characteristics. The particle formulation is uniformly dispersed in the vehicle.
In one embodiment of the present invention the insulinotropic peptide is a glucagon-like peptide-1 (GLP-1), a derivative of GLP-1 (e.g., GLP-1(7-36)amide), or an analogue of GLP-1.
In another embodiment of the present invention insulinotropic peptide is exenatide, a derivative of exenatide, or an analogue of exenatide.
The particle formulation of the present invention typically includes one or more of the following stabilizers: one or more carbohydrate (e.g., a disaccharide, such as, lactose, sucrose, trehalose, cellobiose, and mixtures thereof); one or more antioxidant (e.g., methionine, ascorbic acid, sodium thiosulfate, ethylenediaminetetraacetic acid (EDTA), citric acid, butylated hydroxyltoluene, and mixtures thereof); and one or more buffer (e.g., citrate, histidine, succinate, and mixtures thereof). In a preferred embodiment, the particle formulation comprises an insulinotropic peptide, sucrose, methionine, and citrate buffer. The ratio of insulinotropic peptide to sucrose+methionine is typically about 1/20, about 1/10, about 1/5, about 1/2, about 5/1, about 10/1, or about 20/1, preferably between about 1/5 to 5/1, more preferably between about 1/3 to 3/1. The particle formulation is preferably a particle formulation prepared by spray drying and has a low moisture content, preferably less than or equal to about 10 wt %, more preferably less or equal to about 5 wt %. In another embodiment the particle formulation can be lyophilized.
The suspension vehicle of the present invention comprises one or more solvent and one or more polymer. Preferably the solvent is selected from the group consisting of lauryl lactate, lauryl alcohol, benzyl benzoate, and mixtures thereof. More preferably the solvent is lauryl lactate or benzyl benzoate. Preferably the polymer is a pyrrolidone. In some embodiments the polymer is polyvinylpyrrolidone (e.g., polyvinylpyrrolidone K-17, which typically has an approximate average molecular weight range of 7,900-10,800). In one embodiment of the present invention the solvent consists essentially of benzyl benzoate and polyvinylpyrrolidone.
The suspension formulation typically has a low overall moisture content, for example, less than or equal to about 10 wt % and in a preferred embodiment less than or equal to about 5 wt %.
In another aspect, the present invention relates to an implantable drug delivery device, comprising a suspension formulation of the present invention. In a preferred embodiment, the drug delivery device is an osmotic delivery device.
The present invention further includes methods of manufacturing the suspension formulations of the present invention, as well as osmotic delivery devices loaded with a suspension formulation of the present invention. In one embodiment, the present invention includes a method of manufacturing an osmotic delivery device comprising, loading a suspension formulation into a reservoir of the osmotic delivery device.
In another aspect, the present invention relates to a method of treating diabetes (e.g., diabetes mellitus type 2 or gestational diabetes) in a subject in need of such treatment, comprising delivering a suspension formulation of the present invention from an osmotic delivery device at a substantially uniform rate. Typically the suspension formulation is delivered for a period of about one month to about a year, preferably about three months to about a year. The method may further include subcutaneously inserting an osmotic delivery device, loaded with a suspension formulation of the present invention, into the subject.
In further aspects, the present invention relates to methods of stimulating insulin secretion, suppressing glucagon secretion, slowing gastric emptying, treating diabetic related disorders, treating hyperglycemia, treating obesity, controlling appetite, reducing weight, and regulating gastrointestinal motility.
2.1.0 Formulations and Compositions
2.1.1 Particle Formulations
In one aspect, the present invention provides a pharmaceutical composition comprising a suspension formulation of an insulinotropic peptide, for example, GLP-1 or exenatide. The suspension formulation comprises a non-aqueous, single-phase vehicle including at least one polymer and at least one solvent. The vehicle preferably exhibits viscous fluid characteristics. The peptide component comprises the insulinotropic peptide in a particle formulation that is dispersed in the vehicle. Typically, the particle formulation includes a stabilizing component comprising one of more stabilizer component selected from the group consisting of carbohydrates, antioxidants, amino acids, buffers, and inorganic compounds.
Insulinotropic peptides useful in the practice of the present invention include, but are not limited to, GLP-1 and exenatide.
Bell, G. I., et al., (Nature 302:716-718 (1983)) discovered that proglucagon (Lund, et al., Proc. Natl. Acad. Sci. U.S.A. 79:345-349 (1982); Patzelt, et al., Nature, 282:260-266 (1979)) contained three discrete, highly homologous peptide regions which were designated glucagon, glucagon-like peptide 1 (GLP-1), and glucagon-like peptide 2 (GLP-2). Lopez, et al., (Proc. Natl. Acad. Sci. U.S.A. 80:5485-5489 (1983)) demonstrated that the peptide sequence of GLP-1 was a sequence of 37 amino acids and that the peptide sequence of GLP-2 was a sequence of 34 amino acids.
Studies of the structure of rat preproglucagon revealed a similar pattern of proteolytic cleavage resulting in the formation of glucagon, GLP-1, and GLP-2 (Heinrich, G., et al., Endocrinol., 115:2176-2181 (1984)). Human, rat, bovine, and hamster sequences of GLP-1 were found to be identical (Ghiglione, M., et al., Diabetologia, 27:599-600 (1984)).
Cleavage of preproglucagon first yields GLP-1(1-37), a 37 amino acid peptide that has poor insulinotropic activity. A subsequent cleavage of the peptide bond between amino acid residues 6 and 7 produces a biologically active GLP-1 referred to as GLP-1(7-37) (by convention the amino terminus of GLP-1(7-37) was assigned number 7 and the carboxy terminus number 37). Approximately 80% of GLP-1(7-37) that is produced in mammals is amidated at the C-terminus after removal of the terminal glycine residue in L-cells, resulting in GLP-1(7-36)amide. The biological effects and metabolic turnover of the free acid GLP-1(7-37), and the amide, GLP-1(7-36)amide, are essentially the same. The sequence of GLP-1(7-36)amide is presented in
GLP-1 (including three forms of the peptide, GLP-1(1-37), GLP-1(7-37) and GLP-1(7-36)amide, as well as analogs of GLP-1) have been shown to stimulate insulin secretion (i.e., it is insulinotropic) which induces glucose uptake by cells and results in decreases in serum glucose levels (see, e g., Mojsov, S., Int. J. Peptide Protein Research, 40:333-343 (1992)). Another GLP-1 analogue is liraglutide, which is a long-acting DPP-4-resistant GLP-1 receptor agonist. Liraglutide has 97% identity to GLP-1(7-37). Liraglutide is also called NN-2211 and [Arg34, Lys26]-(N-epsilon-(gamma-Glu(N-alpha-hexadecanoyl))-GLP-1(7-37) (see, e.g., U.S. Pat. No. 6,969,702).
Numerous GLP-1 derivatives and analogues demonstrating insulinotropic action are known in the art (see, e.g., U.S. Pat. Nos. 5,118,666; 5,120,712; 5,512,549; 5,545,618; 5,574,008; 5,574,008; 5,614,492; 5,958,909; 6,191,102; 6,268,343; 6,329,336; 6,451,974; 6,458,924; 6,514,500; 6,593,295; 6,703,359; 6,706,689; 6,720,407; 6,821,949; 6,849,708; 6,849,714; 6,887,470; 6,887,849; 6,903,186; 7,022,674; 7,041,646; 7,084,243; 7,101,843; 7,138,486; 7,141,547; 7,144,863; and 7,199,217). Accordingly, for ease of discussion herein, the family of GLP-1 derivatives and analogues having insulinotropic activity is referred to collectively as GLP-1.
Gastric inhibitory peptide (GIP) is also an insulinotropic peptide (Efendic, S., et al., Horm Metab Res. 36:742-6 (2004)). GIP is a hormone secreted by the mucosa of the duodenum and jejunum in response to absorbed fat and carbohydrate that stimulate the pancreas to secrete insulin. GIP is also known as glucose-dependent insulinotropic polypeptide. GIP is a 42-amino acid gastrointestinal regulatory peptide that stimulates insulin secretion from pancreatic beta cells in the presence of glucose (Tseng, C., et al., PNAS 90:1992-1996 (1993)).
The exendins are peptides that were isolated from the venom of the Gila-monster. Exendin-4 is present in the venom of Heloderma suspectum (Eng, J., et al., J. Biol. Chem., 265:20259-62 (1990); Eng., J., et al., J. Biol. Chem., 267:7402-05 (1992); U.S. Pat. No. 5,424,286). The exendins have some sequence similarity to several members of the glucagon-like peptide family, with the highest homology, 53%, being to GLP-1(7-36)amide (Goke, et al., J. Biol. Chem., 268:19650-55 (1993)).
Exendin-4 acts at GLP-1 receptors on insulin-secreting beta-TC1 cells, dispersed acinar cells from guinea pig pancreas, and parietal cells from stomach. The exendin-4 peptide also stimulates somatostatin release and inhibits gastrin release in isolated stomachs (Goke, et al., J. Biol. Chem. 268:19650-55 (1993); Schepp, et al., Eur. J. Pharmacol., 69:183-91 (1994); Eissele, et al., Life Sci., 55:629-34 (1994)). Based on their insulinotropic activities, use of exendin-3 and exendin-4 for the treatment of diabetes mellitus and the prevention of hyperglycemia has been proposed (U.S. Pat. No. 5,424,286).
Numerous exendin-4 derivatives and analogues (including, e.g., exendin-4 agonists) demonstrating insulinotropic action are known in the art (see, e.g., U.S. Pat. Nos. 5,424,286; 6,268,343; 6,329,336; 6,506,724; 6,514,500; 6,528,486; 6,593,295; 6,703,359; 6,706,689; 6,767,887; 6,821,949; 6,849,714; 6,858,576; 6,872,700; 6,887,470; 6,887,849; 6,924,264; 6,956,026; 6,989,366; 7,022,674; 7,041,646; 7,115,569; 7,138,375; 7,141,547; 7,153,825; and 7,157,555). Exenatide is a synthetic peptide having the same 39 amino acid sequence as exendin-4. Exenatide is a peptide incretin mimetic that exhibits glucoregulatory activities similar to the mammalian incretin hormone glucagon-like peptide 1 (GLP-1). Incretin hormones are hormones that cause an increase in the amount of insulin released when glucose levels are normal or particularly when they are elevated. Incretin hormones affect other activities defined by insulin secretion, for example, they can reduce glucagon production and delay gastric emptying. Further, incretin hormones may improve insulin sensitivity and possibly increase islet cell neogenesis.
For ease of discussion herein, the family of exendin-4 peptides, including synthetic versions (e.g., exenatide), derivatives and analogues having insulinotropic activity, is referred to collectively as exenatide.
In one aspect, the present invention provides particle formulations of insulinotropic peptides that can be used to prepare suspension formulations. The insulinotropic peptides of the present invention shall not be limited by method of synthesis or manufacture and shall include those obtained from natural sources, or synthesized or manufactured by recombinant (whether produced from cDNA or genomic DNA), synthetic, transgenic, and gene-activated methods. In preferred embodiments of the present invention the insulinotropic peptide is a GLP-1 peptide or an exendin peptide (as described herein above), for example, GLP-1(7-36)amide or exenatide. The present invention also includes combinations of two or more insulinotropic peptides, for example, GLP-1(7-36)amide and GIP.
Particle formulations of the invention are preferably chemically and physically stable for at least 1 month, preferably at least 3 months, more preferably at least 6 months, more preferably at least 12 months at delivery temperature. The delivery temperature is typically normal human body temperature, for example, about 37° C., or slightly higher, for example, about 40° C. Further, particle formulations of the present invention are preferably chemically and physically stable for at least 3 months, preferably at least 6 months, more preferably at least 12 months, at storage temperature. Examples of storage temperatures include refrigeration temperature, for example, about 5° C., or room temperature, for example, about 25° C.
A particle formulation may be considered chemically stable if less than about 25%, preferably less than about 20%, more preferably less than about 15%, more preferably less than about 10%, and more preferably less than about 5% breakdown products of the peptide particles are formed after about 3 months, preferably after about 6 months, preferably after about 12 months at delivery temperature and after about 6 months, after about 12 months, and preferably after about 24 months at storage temperature.
A particle formulation may be considered physically stable if less than about 10%, preferably less than about 5%, more preferably less than about 3%, more preferably less than 1% aggregates of the peptide particles are formed after about 3 months, preferably after about 6 months, at delivery temperature and about 6 months, preferably about 12 months, at storage temperature.
To preserve protein stability generally an insulinotropic peptide solution is kept in a frozen condition and lyophilized or spray dried to a solid state. Tg (glass transition temperature) may be one factor to consider in achieving stable compositions of peptide. While not intending to be bound by any particular theory, the theory of formation of a high Tg amorphous solid to stabilize peptides, polypeptides, or proteins has been utilized in pharmaceutical industry. Generally, if an amorphous solid has a higher Tg, such as 100° C., peptide products will not have mobility when stored at room temp or even at 40° C. because the storage temperature is below the Tg. Calculations using molecular information have shown that if a glass transition temperature is above a storage temperature of 50° C. that there is zero mobility for molecules. No mobility of molecules correlates with no instability issues. Tg is also dependent on the moisture level in the product formulation. Generally, the more moisture, the lower the Tg of the composition.
Accordingly, in some aspects of the present invention, excipients with higher Tg may be included in the protein formulation to improve stability, for example, sucrose (Tg=75° C.) and trehalose (Tg=110° C.). Preferably, particle formulations are formable into particles using processes such as spray drying, lyophilization, desiccation, freeze-drying, milling, granulation, ultrasonic drop creation, crystallization, precipitation, or other techniques available in the art for forming particles from a mixture of components. The particles are preferably substantially uniform in shape and size.
A typical spray dry process may include, for example, loading a spray solution containing a peptide, for example, an insulinotropic peptide (e.g., GLP-1(7-36)amide or exenatide), and stabilizing excipients into a sample chamber. The sample chamber is typically maintained at a desired temperature, for example, refrigeration to room temperature. Refrigeration generally promotes stability of the protein. A solution, emulsion, or suspension is introduced to the spray dryer where the fluid is atomized into droplets. Droplets can be formed by use of a rotary atomizer, pressure nozzle, pneumatic nozzle, or sonic nozzle. The mist of droplets is immediately brought into contact with a drying gas in a drying chamber. The drying gas removes solvent from the droplets and carries the particles into a collection chamber. In spray drying, factors that can affect yield include, but are not limited to, localized charges on particles (which may promote adhesion of the particles to the spray dryer) and aerodynamics of the particles (which may make it difficult to collect the particles). In general, yield of the spray dry process depends in part on the particle formulation.
In one embodiment of the present invention, the particles are sized such that they can be delivered via an implantable drug delivery device. Uniform shape and size of the particles typically helps to provide a consistent and uniform rate of release from such a delivery device; however, a particle preparation having a non-normal particle size distribution profile may also be used. For example, in a typical implantable osmotic delivery device having a delivery orifice, the size of the particles is less than about 30%, preferably is less than about 20%, more preferably is less than about than 10%, of the diameter of the delivery orifice. In an embodiment of the particle formulation for use with an osmotic delivery system, wherein the delivery orifice diameter of the implant is in a range of, for example, about 0.1 to about 0.5 mm, particle sizes may be preferably less than about 50 microns, more preferably less than about 10 microns, more preferably in a range from about 3 to about 7 microns. In one embodiment, the orifice is about 0.25 mm (250 μm) and the particle size is approximately 3-5 μm.
In a preferred embodiment, when the particles are incorporated in a suspension vehicle they do not settle in less than about 3 months at delivery temperature. Generally speaking, smaller particles tend to have a lower settling rate in viscous suspension vehicles than larger particles. Accordingly, micron- to nano-sized particles are typically desirable. In an embodiment of the particle formulation of the present invention for use in an implantable osmotic delivery device, wherein the delivery orifice diameter of the implant is in a range of, for example, about 0.1 to about 0.5 mm, particle sizes may be preferably less than about 50 microns, more preferably less than about 10 microns, more preferably in a range from about 3 to about 7 microns.
In one embodiment, a particle formulation of the present invention comprises one or more insulinotropic peptide, as described above, one or more stabilizers, and optionally a buffer. The stabilizers may be, for example, carbohydrate, antioxidant, amino acid, buffer, or inorganic compound. The amounts of stabilizers and buffer in the particle formulation can be determined experimentally based on the activities of the stabilizers and buffers and the desired characteristics of the formulation. Typically, the amount of carbohydrate in the formulation is determined by aggregation concerns. In general, the carbohydrate level should not be too high so as to avoid promoting crystal growth in the presence of water due to excess carbohydrate unbound to insulinotropic peptide. Typically, the amount of antioxidant in the formulation is determined by oxidation concerns, while the amount of amino acid in the formulation is determined by oxidation concerns and/or formability of particles during spray drying. Typically, the amount of buffer in the formulation is determined by pre-processing concerns, stability concerns, and formability of particles during spray drying. Buffer may be required to stabilize insulinotropic peptide during processing, e.g., solution preparation and spray drying, when all excipients are solubilized.
Examples of carbohydrates that may be included in the particle formulation include, but are not limited to, monosaccharides (e.g., fructose, maltose, galactose, glucose, D-mannose, and sorbose), disaccharides (e.g., lactose, sucrose, trehalose, and cellobiose), polysaccharides (e.g., raffinose, melezitose, maltodextrins, dextrans, and starches), and alditols (acyclic polyols; e.g., mannitol, xylitol, maltitol, lactitol, xylitol sorbitol, pyranosyl sorbitol, and myoinsitol). Preferred carbohydrates include non-reducing sugars, such as sucrose, trehalose, and raffinose.
Examples of antioxidants that may be included in the particle formulation include, but are not limited to, methionine, ascorbic acid, sodium thiosulfate, catalase, platinum, ethylenediaminetetraacetic acid (EDTA), citric acid, cysteins, thioglycerol, thioglycolic acid, thiosorbitol, butylated hydroxanisol, butylated hydroxyltoluene, and propyl gallate.
Examples of amino acids that may be included in the particle formulation include, but are not limited to, arginine, methionine, glycine, histidine, alanine, L-leucine, glutamic acid, iso-leucine, L-threonine, 2-phenylamine, valine, norvaline, praline, phenylalanine, trytophan, serine, asparagines, cysteine, tyrosine, lysine, and norleucine. Preferred amino acids include those that readily oxidize, e.g., cysteine, methionine, and trytophan.
Examples of buffers that may be included in the particle formulation include, but are not limited to, citrate, histidine, succinate, phosphate, maleate, tris, acetate, carbohydrate, and gly-gly. Preferred buffers include citrate, histidine, succinate, and tris.
Examples of inorganic compounds that may be included in the particle formulation include, but are not limited to, NaCl, Na2SO4, NaHCO3, KCl, KH2PO4, CaCl2, and MgCl2.
In addition, the particle formulation may include other excipients, such as surfactants, bulking agents, and salts. Examples of surfactants include, but are not limited to, Polysorbate 20, Polysorbate 80, PLURONIC® (BASF Corporation, Mount Olive, N.J.) F68, and sodium docecyl sulfate (SDS). Examples of bulking agents include, but are not limited to, mannitol and glycine. Examples of salts include, but are not limited to, sodium chloride, calcium chloride, and magnesium chloride.
All components included in the particle formulation are typically acceptable for pharmaceutical use in mammals, in particular, in humans.
Table 1 below presents examples of particle formulation composition ranges for particles comprising exenatide.
In one embodiment, the exenatide particle formulation comprises exenatide peptide, sucrose (carbohydrate), methionine (antioxidant), and sodium citrate/citric acid (citrate buffer).
Table 2 below presents examples of particle formulation composition ranges for particles comprising GLP-1.
Within these weight percent ranges for components of the particle formulation, some preferred component ratios are as follows: insulinotropic peptide (e.g., exenatide or GLP-1) to antioxidant (e.g., methionine)⇒1/10, 1/5, 1/2.5, 1/1, 2.5/1, 5/1, 10/1, preferably between about 1/5 to 5/1, more preferably between about 1/3 to 3/1 (these same component ratios apply to insulinotropic peptide to amino acid ratios); insulinotropic peptide (e.g., exenatide or GLP-1) to carbohydrate (e.g., sucrose)—1/10, 1/5, 1/2.5, 1/1, 2.5/1, 5/1, 10/1, preferably between about 1/5 to 5/1, more preferably between about 1/3 to 3/1; and/or insulinotropic peptide (e.g., exenatide or GLP-1) to antioxidant+carbohydrate (e.g., methionine+sucrose)—1/20, 1/10, 1/5, 1/2, 5/1, 10/1, 20/1, preferably between about 1/5 to 5/1, more preferably between about 1/3 to 3/1 (these same component ratios apply to insulinotropic peptide to amino acid+carbohydrate ratios). The present invention also includes ranges corresponding to all of these ratios, for example, between about 1/20 and about 20/1, between about 1/10 and about 10/1, between about 1/5 and about 5/1, and so on, as well as, for example, between about 1/5 and about 3/1, and so on.
In summary, insulinotropic peptides are formulated into dried powders in solid state, which preserve maximum chemical and biological stability of proteins or peptides. The particle formulation offers long term storage stability at high temperature, and therefore, allows delivery to a subject of stable and biologically effective peptide for extended periods of time.
Particle size distribution of the dry particle powder can be well controlled (0.1 micron-20 micron), for example, by using the methods of spray drying or lyophilization to prepare the particle formulations. The process parameters for formation of the dry powder are optimal to produce particles with desired particle size distribution, density, and surface area.
The selected excipients and buffer in the particle formulation may provide, for example, the following functions: density modification of the dry powder; preservation of the peptide chemical stability; maintenance of the peptide's physical stability (e.g., high glass transition temperature, and avoiding phase to phase transition); producing homogenous dispersions in suspension by use of bulking agents; modification of hydrophobicity and/or hydrophilicity to manipulate dry powder solubility in selected solvents; and, manipulation of pH during processing and maintenance of pH in the product (for solubility and stability).
The particle formulations of the present invention are exemplified herein below with reference to exenatide and GLP-1(7-36)amide as exemplary insulinotropic peptides (see, Example 1 and Example 2). These examples are not intended to be limiting.
2.1.2 Vehicle and Suspension Formulations
In one aspect of the present invention, the suspension vehicle provides a stable environment in which the insulinotropic peptide particle formulation is dispersed. The particle formulations are chemically and physically stable (as described above) in the suspension vehicle. The suspension vehicle typically comprises one or more polymers and one or more solvents that form a solution of sufficient viscosity to uniformly suspend the particles comprising the insulinotropic peptide.
The viscosity of the suspension vehicle is typically sufficient to prevent the particle formulation from settling during storage and use in a method of delivery, for example, in an implantable, drug delivery device. The suspension vehicle is biodegradable in that the suspension vehicle disintegrates or breaks down over a period of time in response to a biological environment. The disintegration of the suspension vehicle may occur by one or more physical or chemical degradative processes, such as by enzymatic action, oxidation, reduction, hydrolysis (e.g., proteolysis), displacement (e.g., ion exchange), or dissolution by solubilization, emulsion or micelle formation. After the suspension vehicle disintegrates, components of the suspension vehicle are absorbed or otherwise dissipated by the body and surrounding tissue of the patient.
The solvent in which the polymer is dissolved may affect characteristics of the suspension formulation, such as the behavior of the insulinotropic peptide particle formulation during storage. A solvent may be selected in combination with a polymer so that the resulting suspension vehicle exhibits phase separation upon contact with the aqueous environment. In some embodiments of the invention, the solvent may be selected in combination with the polymer so that the resulting suspension vehicle exhibits phase separation upon contact with the aqueous environment having less than approximately about 10% water.
The solvent may be an acceptable solvent that is not miscible with water. The solvent may also be selected so that the polymer is soluble in the solvent at high concentrations, such as at a polymer concentration of greater than about 30%. However, typically the insulinotropic peptide is substantially insoluble in the solvent. Examples of solvents useful in the practice of the present invention include, but are not limited to, lauryl alcohol, benzyl benzoate, benzyl alcohol, lauryl lactate, decanol (also called decyl alcohol), ethyl hexyl lactate, and long chain (C8 to C24) aliphatic alcohols, esters, or mixtures thereof. The solvent used in the suspension vehicle may be “dry,” in that it has a low moisture content. Preferred solvents for use in formulation of the suspension vehicle include lauryl lactate, lauryl alcohol, benzyl benzoate, and combinations thereof.
Examples of polymers for formulation of the suspension vehicles of the present invention include, but are not limited to, a polyester (e.g., polylactic acid or polylacticpolyglycolic acid), pyrrolidone (e.g., polyvinylpyrrolidone (PVP) having a molecular weight ranging from approximately 2,000 to approximately 1,000,000), ester or ether of an unsaturated alcohol (e.g., vinyl acetate), polyoxyethylenepolyoxypropylene block copolymer, or mixtures thereof. In one embodiment, the polymer is PVP having a molecular weight of 2,000 to 1,000,000. In a preferred embodiment the polymer is polyvinylpyrrolidone K-17 (typically having an approximate average molecular weight range of 7,900-10,800). Polyvinylpyrrolidone can be characterized by its K-value (e.g., K-17), which is a viscosity index. The polymer used in the suspension vehicle may include one or more different polymers or may include different grades of a single polymer. The polymer used in the suspension vehicle may also be dry or have a low moisture content.
Generally speaking, a suspension vehicle according to the present invention may vary in composition based on the desired performance characteristics. In one embodiment, the suspension vehicle may comprise about 40% to about 80% (w/w) polymer(s) and about 20% to about 60% (w/w) solvent(s). Preferred embodiments of a suspension vehicle include vehicles formed of polymer(s) and solvent(s) combined at the following ratios: about 25% solvent and about 75% polymer; about 50% solvent and about 50% polymer; about 75% solvent and about 25% polymer.
The suspension vehicle may exhibit Newtonian behavior. The suspension vehicle is typically formulated to provide a viscosity that maintains a uniform dispersion of the particle formulation for a predetermined period of time. This helps facilitate making a suspension formulation tailored to provide controlled delivery of the insulinotropic peptide at a desired rate. The viscosity of the suspension vehicle may vary depending on the desired application, the size and type of the particle formulation, and the loading of the particle formulation in the suspension vehicle. The viscosity of the suspension vehicle may be varied by altering the type or relative amount of the solvent or polymer used.
The suspension vehicle may have a viscosity ranging from about 100 poise to about 1,000,000 poise, preferably from about 1,000 poise to about 100,000 poise. The viscosity may be measured at 37° C., at a shear rate of 10−4/sec, using a parallel plate rheometer. In some embodiments, the viscosity of the suspension vehicle ranges from approximately 5,000 poise to approximately 50,000 poise. In preferred embodiments, the viscosity range is between about 12,000 to about 18,000 poise at 33° C.
The suspension vehicle may exhibit phase separation when contacted with the aqueous environment; however, typically the suspension vehicle exhibits substantially no phase separation as a function of temperature. For example, at a temperature ranging from approximately 0° C. to approximately 70° C. and upon temperature cycling, such as cycling from 4° C. to 37° C. to 4° C., the suspension vehicle typically exhibits no phase separation.
The suspension vehicle may be prepared by combining the polymer and the solvent under dry conditions, such as in a dry box. The polymer and solvent may be combined at an elevated temperature, such as from approximately 40° C. to approximately 70° C., and allowed to liquefy and form the single phase. The ingredients may be blended under vacuum to remove air bubbles produced from the dry ingredients. The ingredients may be combined using a conventional mixer, such as a dual helix blade or similar mixer, set at a speed of approximately 40 rpm. However, higher speeds may also be used to mix the ingredients. Once a liquid solution of the ingredients is achieved, the suspension vehicle may be cooled to room temperature. Differential scanning calorimetry (DSC) may be used to verify that the suspension vehicle is a single phase. Further, the components of the vehicle (e.g., the solvent and/or the polymer) may be treated to substantially reduce or substantially remove peroxides (e.g., by treatment with methionine; see, e.g., U.S., Patent Application Publication No. 2007-0027105).
The particle formulation, comprising an insulinotropic peptide, is added to the suspension vehicle to form a suspension formulation. The suspension formulation may be prepared by dispersing the particle formulation in the suspension vehicle. The suspension vehicle may be heated and the particle formulation added to the suspension vehicle under dry conditions. The ingredients may be mixed under vacuum at an elevated temperature, such as from about 40° C. to about 70° C. The ingredients may be mixed at a sufficient speed, such as from about 40 rpm to about 120 rpm, and for a sufficient amount of time, such as about 15 minutes, to achieve a uniform dispersion of the particle formulation in the suspension vehicle. The mixer may be a dual helix blade or other suitable mixer. The resulting mixture may be removed from the mixer, sealed in a dry container to prevent water from contaminating the suspension formulation, and allowed to cool to room temperature before further use, for example, loading into an implantable, drug delivery device, unit dose container, or multiple-dose container.
The suspension formulation typically has an overall moisture content of less than about 10 wt %, preferably less than about 5 wt %, and more preferably less than about 4 wt %.
The suspension formulations of the present invention are exemplified herein below with reference to exenatide and GLP-1(7-36)amide as exemplary insulinotropic peptides (see, Example 3 and Example 4). These examples are not intended to be limiting.
In summary, the components of the suspension vehicle provide biocompatibility. Components of the suspension vehicle offer suitable chemico-physical properties to form stable suspensions of, for example, dry powder particle formulations. These properties include, but are not limited to, the following: viscosity of the suspension; purity of the vehicle; residual moisture of the vehicle; density of the vehicle; compatibility with the dry powders; compatibility with implantable devices; molecular weight of the polymer; stability of the vehicle; and hydrophobicity and hydrophilicity of the vehicle. These properties can be manipulated and controlled, for example, by variation of the vehicle composition and manipulation of the ratio of components used in the suspension vehicle.
The suspension formulations described herein may be used in an implantable, drug delivery device to provide sustained delivery of a compound over an extended period of time, such as over weeks, months, or up to about one year. Such an implantable drug delivery device is typically capable of delivering the compound at a desired flow rate over a desired period of time. The suspension formulation may be loaded into the implantable, drug delivery device by conventional techniques.
The suspension formulation may be delivered, for example, using an osmotically, mechanically, electromechanically, or chemically driven drug delivery device. The insulinotropic peptide is delivered at a flow rate that is therapeutically effective to the subject in need of treatment by the insulinotropic peptide.
The insulinotropic peptide may be delivered over a period ranging from more than about one week to about one year or more, preferably for about one month to about a year or more, more preferably for about three months to about a year or more. The implantable, drug delivery device may include a reservoir having at least one orifice through which the insulinotropic peptide is delivered. The suspension formulation may be stored within the reservoir. In one embodiment, the implantable, drug delivery device is an osmotic delivery device, wherein delivery of the drug is osmotically driven. Some osmotic delivery devices and their component parts have been described, for example, the DUROS® delivery device or similar devices (see, e.g., U.S. Pat. Nos. 5,609,885; 5,728,396; 5,985,305; 5,997,527; 6,113,938; 6,132,420; 6,156,331; 6,217,906; 6,261,584; 6,270,787; 6,287,295; 6,375,978; 6,395,292; 6,508,808; 6,544,252; 6,635,268; 6,682,522; 6,923,800; 6,939,556; 6,976,981; 6,997,922; 7,014,636; 7,207,982; 7,112,335; 7,163,688; U.S. Patent Publication Nos. 2005-0175701, 2007-0281024, and 2008-0091176).
The DUROS® delivery device typically consists of a cylindrical reservoir which contains the osmotic engine, piston, and drug formulation. The reservoir is capped at one end by a controlled-rate water-permeable membrane and capped at the other end by a diffusion moderator through which drug formulation is released from the drug reservoir. The piston separates the drug formulation from the osmotic engine and utilizes a seal to prevent the water in the osmotic engine compartment from entering the drug reservoir. The diffusion moderator is designed, in conjunction with the drug formulation, to prevent body fluid from entering the drug reservoir through the orifice.
The DUROS® device releases a therapeutic agent at a predetermined rate based on the principle of osmosis. Extracellular fluid enters the DUROS® device through a semi-permeable membrane directly into a salt engine that expands to drive the piston at a slow and even delivery rate. Movement of the piston forces the drug formulation to be released through the orifice or exit port at a predetermined sheer rate. In one embodiment of the present invention, the reservoir of the DUROS® device is load with a suspension formulation of the present invention, comprising, for example, GLP-1(7-36)amide or exenatide, wherein the device is capable of delivering the suspension formulation to a subject over an extended period of time (e.g., about 3, about 6, or about 12 months) at a predetermined, therapeutically effective delivery rate.
Implantable devices, for example, the DUROS® device, provide the following advantages for administration of a beneficial agent formulation: true zero-order release of the beneficial agent pharmacokinetically; long-term release period time (e.g., up to about 12 months); and reliable delivery and dosing of a beneficial agent.
Other implantable, drug delivery devices may be used in the practice of the present invention and may include regulator-type implantable pumps that provide constant flow, adjustable flow, or programmable flow of the compound, such as those available from Codman & Shurtleff, Inc. (Raynham, Mass.), Medtronic, Inc. (Minneapolis, Minn.), and Tricumed Medinzintechnik GmbH (Germany).
Implantable devices, for example, the DUROS® device, provide the following advantages for administration of the suspension formulations of the present invention: true zero-order release of the insulinotropic peptide pharmacokinetically; long-term release period time (e.g., up to about 12 months); and reliable delivery and dosing of the insulinotropic peptide.
The amount of beneficial agent employed in the delivery device of the invention is that amount necessary to deliver a therapeutically effective amount of the agent to achieve the desired therapeutic result. In practice, this will vary depending upon such variables, for example, as the particular agent, the site of delivery, the severity of the condition, and the desired therapeutic effect. Typically, for an osmotic delivery device, the volume of a beneficial agent chamber comprising the beneficial agent formulation is between about 100 μl to about 1000 μl, more preferably between about 120 μl and about 500 μl, more preferably between about 150 μl and about 200 μl.
Typically, the osmotic delivery device is implanted within the subject, for example, subcutaneously. The device(s) can be inserted in either or both arms (e.g., in the inside, outside, or back of the upper arm) or into the abdomen. Preferred locations in the abdomen are under the abdominal skin in the area extending below the ribs and above the belt line. To provide a number of locations for insertion of one or more osmotic delivery device within the abdomen, the abdominal wall can be divided into 4 quadrants as follows: the upper right quadrant extending 5-8 centimeters below the right ribs and about 5-8 centimeters to the right of the midline, the lower right quadrant extending 5-8 centimeters above the belt line and 5-8 centimeters to the right of the midline, the upper left quadrant extending 5-8 centimeters below the left ribs and about 5-8 centimeters to the left of the midline, and the lower left quadrant extending 5-8 centimeters above the belt line and 5-8 centimeters to the left of the midline. This provides multiple available locations for implantation of one or more devices on one or more occasions.
The suspension formulation may also be delivered from a drug delivery device that is not implantable or implanted, for example, an external pump such as a peristaltic pump used for subcutaneous delivery in a hospital setting.
The suspension formulations of the present invention may also be used in infusion pumps, for example, the ALZET® (DURECT Corporation, Cupertino Calif.) osmotic pumps which are miniature, infusion pumps for the continuous dosing of laboratory animals (e.g., mice and rats).
The suspension formulations of the present invention may also be used in the form of injections to provide highly concentrated bolus doses of biologically active insulinotropic peptides.
In one embodiment of the present invention, the continuous delivery of, for example, derivatives and analogues of GLP-1 that have short half-lives after injection into humans (e.g., GLP-1(7-36)amide or exenatide) from an implantable device would be particularly beneficial. Further, the use of an implantable device, such as the DUROS® device, to deliver insulinotropic peptides could reduce injection-related side-effects and, with increased convenience of dosing, result in increased treatment compliance. The duration of drug delivery from one implant may be weeks or as long as one year.
Some advantages and benefits of the suspension formulations of the present invention delivered via an osmotic delivery device, such as a DUROS® device, include, but are not limited to the following. Increased treatment compliance can result in better efficacy and such increased compliance can be achieved using an implanted osmotic delivery device. Efficacy of treatment can be improved because an implantable osmotic device, such as a DUROS® device, can provide continuous and consistent delivery of drug (e.g., GLP-1 or exenatide) 24 hours per day to provide better control of blood glucose levels day and night. Further, it is believed that incretins and incretin mimetics may protect the beta cells in the pancreas and slow down the progression of type 2 diabetes mellitus. Twenty-four hour continuous and consistent drug delivery of incretins or incretin mimetics from the DUROS® device thus can provide even greater protection of the beta cells and may provide reversal of the disease progression. Continuous delivery of insulinotropic peptides (e.g., GLP-1 or exenatide) from the DUROS® device also allows treated subjects complete flexibility in planning meals and thus an increased quality of life compared to, for example, treatment with bolus injections that need to be timed relative to the major meals of the day. Also, unlike other sustained release formulations and depot injections, drug dosing when using a DUROS® device can be immediately halted by removal of the device, for example, if a safety issue arises for a particular subject.
In addition to GLP-1 derivatives and analogues demonstrating insulinotropic action, other derivatives of GLP-1 (e.g., GLP-1(9-36) amide) have been shown to reduce blood glucose by a mechanism that does not involve insulin secretion (Deacon, C. F., et al., Am. J. Physiol. Endocrinol. Metab. 282:E873-E879 (2002)). Further, GLP-1(9-36) amide has been shown to reduce postprandial glycemia independently of gastric emptying and insulin secretion (Meier, J. J., et al., Am. J. Physiol. Endocrinol. Metab. 290:E1118-E1123 (2006)). Accordingly, in another aspect, the present invention includes formulation of such GLP-1 derivatives into particles, suspension of the particles in a vehicle, and delivery of these suspension formulations to subjects to reduce blood glucose and/or to reduce postprandial glycemia essentially as described herein above for GLP-1 derivatives and analogues demonstrating insulinotropic action. In addition, GIP(3-42) appears to be a weak GIP receptor antagonist that does not exert insulin-related glucoregulation. Such GIP derivatives may also be formulated (singly or in combination with other peptides) following the guidance presented herein.
The present invention also includes methods of manufacturing the formulations of the present invention, including the particle formulations, suspension vehicles, and suspension formulations described herein above.
The suspension formulations as described herein provide promising alternatives to insulin therapy for subjects with diabetes mellitus. Diabetes mellitus type 2 or Type 2 Diabetes (also called non-insulin-dependent diabetes mellitus (NIDDM) or adult-onset diabetes) is a metabolic disorder that is primarily characterized by insulin resistance, relative insulin deficiency and hyperglycemia. The suspension formulations of the present invention, comprising insulinotropic peptides, are useful for stimulating insulin secretion, suppressing glucagon secretion, slowing gastric emptying, and possibly enhancing insulin sensitivity in peripheral tissues such as muscle and fat.
The suspension formulations of the present invention may be useful in the treatment of diabetes (e.g., diabetes mellitus, and gestational diabetes), and diabetic related disorders (e.g., diabetic cardiomyopathy, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, and tissue ischemia, particularly myocardial ischemia), as well as, hyperglycemia (e.g., related to treatment with medications that increase the risk of hyperglycemia, including beta blockers, thiazide diuretics, corticosteroids, niacin, pentamidine, protease inhibitors, L-asparaginase, and some antipsychotic agents), reducing food intake (e.g., treating obesity, controlling appetite, or reducing weight), stroke, lowering plasma lipids, acute coronary syndrome, hibernating myocardium, regulating gastrointestinal motility, and increasing urine flow.
In addition, the suspension formulations of the present invention may be potential regulators of appetite in subjects treated with the formulations.
In one embodiment, suspension formulations are administered using an osmotic delivery device as described above. Examples of target rates of delivery for suspension formulations of the present invention, comprising insulinotropic peptides, include, but are not limited to: suspension formulations comprising particle formulations comprising GLP-1 (e.g., GLP-1(7-36)amide), between about 20 μg/day and about 900 μg/day, preferably between about 100 μg/day and about 600 μg/day, for example, at about 480 μg/day; and suspension formulations comprising particle formulations comprising exenatide, between about 5 μg/day and about 320 μg/day, preferably between about 5 μg/day and about 160 μg/day, for example, at about 10 μg/day to about 20 μg/day. An exit sheer rate of the suspension formulation from the osmotic delivery device is determined such that the target daily target delivery rate of the insulinotropic peptide is reasonably achieved by substantially continuous, uniform delivery of the suspension formulation from the osmotic delivery device. Examples of exit sheer rates include, but are not limited to, about 1 to about 1×10−7 reciprocal second, preferably about 4×10−2 to about 6×10−4 reciprocal second, more preferably 5×10−3 to 1×10−3 reciprocal second.
A subject being treated with the suspension formulations of the present invention may also benefit from co-treatment with other agents (e.g., sulfonylureas, meglitinides (e.g., repaglinide, and nateglinide), metformin, and combinations of such agents), alpha glucosidase inhibitors, amylin (as well as synthetic analogues such as pramlintide), dipeptidyl peptidase IV (DPP-IV) inhibitors (e.g., sitagliptin and vildagliptin), and long/short acting insulins.
Use of oral dipeptidyl peptidase-IV (DPP-IV or DPP-4) inhibitors orally to prevent cleavage of GLP-1 may be particularly useful when the suspension formulation of the present invention comprises a GLP-1 variant that is cleavable by dipeptidyl peptidase-IV (see, e.g., U.S. Pat. No. 7,205,409).
Example 5 presents data demonstrating that delivery of a formulation comprising exenatide using the DUROS® device resulted in decreased glucose levels and weight loss in treated animals.
Other objects may be apparent to one of ordinary skill upon reviewing the following specification and claims.
The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the devices, methods, and formulae of the present invention, and are not intended to limit the scope of what the inventor regards as the invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.
The compositions produced according to the present invention meet the specifications for content and purity required of pharmaceutical products.
This example describes making exenatide particle formulations.
A. Formulation 1
Exenatide (0.25 g) was dissolved in 50 mM sodium citrate buffer at pH 6.04. The solution was dialyzed with a formulation solution containing sodium citrate buffer, sucrose, and methionine. The formulated solution was then spray dried using Buchi 290 with 0.7 mm nozzle, outlet temperature of 75° C., atomization pressure of 100 Psi, solid content of 2%, and flow rate of 2.8 mL/min. The dry powder contained 21.5% of exenatide with 4.7% residual moisture and 0.228 g/ml density.
B. Formulations 2 and 3
Two additional formulations of exenatide were prepared essentially by the method just described. Following here in Table 3 is a summary of the weight percentages (wt %) of the components of the Formulations 1, 2 and 3.
This example describes making an GLP-1(7-36)amide particle formulation. GLP-1(7-36)amide (1.5 g) was dissolved in 5 mM sodium citrate buffer at pH 4. The solution was dialyzed with a formulation solution containing sodium citrate buffer and methionine. The formulated solution was then spray dried using Buchi 290 with 0.7 mm nozzle, outlet temperature of 70° C., atomization pressure of 100 Psi, solid content of 1.5%, and flow rate of 5 mL/min. The dry powder contained 90% of GLP-1(7-36)amide.
This example describes making suspension formulations comprising a suspension vehicle and an exenatide particle formulation.
A. Suspension Formulation of 20 wt % Exenatide Particles
An exenatide particle formulation was generated by spray-drying, and contained 20 wt % exenatide, 32 wt % sucrose, 16 wt % methionine and 32 wt % citrate buffer.
A suspension vehicle was formed by dissolving the polymer polyvinylpyrrolidone in the solvent benzyl benzoate at approximately a 50/50 ratio by weight. The vehicle viscosity was approximately 12,000 to 18,000 poise when measured at 33° C. Particles containing the peptide exenatide were dispersed throughout the vehicle at a concentration of 10% particles by weight.
B. Suspension Formulations of Particle Formulations 1, 2, and 3
A suspension vehicle was formed by dissolving the polymer polyvinylpyrrolidone K-17 (typically having an approximate average molecular weight range of 7,900-10,800) in the solvent benzyl benzoate heated to approximately 65° C. under a dry atmosphere and reduced pressure at approximately a 50/50 ratio by weight. The vehicle viscosity was approximately 12,000 to 18,000 poise when measured at 33° C. Particle formulations 1-3, described in Example 1, were dispersed throughout the vehicle at the concentrations (by weight percent) shown in Table 4.
This example describes making a suspension formulation comprising a suspension vehicle and an GLP-1(7-36)amide particle formulation. A GLP-1(7-36)amide particle formulation was generated by spray-drying, and contained 90 wt % GLP-1, 5 wt % methionine and 5 wt % citrate buffer.
A suspension vehicle containing the polymer polyvinylpyrrolidone was dissolved in the solvent benzyl benzoate at approximately a 50/50 ratio by weight. The vehicle viscosity was approximately 12,000 to 18,000 poise when measured at 33° C. Particles containing the peptide GLP-1(7-36)amide were dispersed throughout the vehicle at a concentration of 33% particles by weight.
The data in this Example demonstrated the effect of continuous and consistent delivery of an exenatide formulation from the DUROS® device on glucose levels and weight in the Zucker Diabetic Fatty (ZDF) rat model of type 2 diabetes.
The ZDF rat model has been previously described as an accurate model for Type 2 diabetes based on impaired glucose tolerance caused by the inherited obesity gene mutation which leads to insulin resistance (see, e.g., Clark, J., et al., Proc. Soc. Exp. Biol. Med. 173: 68-75 (1983); Peterson, R. G., et al., ILAR News 32: 16-19 (1990); Peterson, R. G., In Frontiers in Diabetes Research. Lessons from Animal Diabetes III, edited by E. Shafrir, pp. 456-458. London: Smith-Gordon (1990); Vrabec, J. T., Otolaryngol Head Neck Surg 118: 304-308 (1998); Sparks, J. D., et al., Metabolism 47: 1315-1324 (1998)). The study design presented in Table 5 was used.
Rats (Group 2, obese, and Group 3, lean, n=6/group) in treatment groups were exposed to 20 mcg/day of exenatide (Suspension Formulation 2; Example 3, Table 4) continuously delivered using DUROS® devices for seven 24 hour periods (wherein the device was inserted on day 1 and removed on day 8), while placebo devices were inserted into rats in the control group (Group 1; n=6). The DUROS® devices were inserted subcutaneously into each of the animals.
Over the treatment period the following endpoints were evaluated. Clinical signs/Mortality were assessed at least once daily. Body weight was determined prior to implantation, daily during the observation period, and at termination. Blood glucose was determined as follows: fasted blood samples collected on Days −1 and 8; and un-fasted blood samples were taken three times each day (4-6 hours apart) Days −1 and 8, with two un-fasted blood samples taken on Days −1 and 8. Blood glucose was determined using a OneTouch Ultra® (Johnson & Johnson, New Brunswick N.J.) blood glucose meter. Glucose levels were measured three times per day. Quantitative HbA1c was determined for fasted blood samples collected on Days −1 and 8 using a DCA 2000 Plus Analyzer (GMI, Inc., Ramsey Minn.). Serial blood samples were obtained pre-Implant (0), at 12, 24, 36, 48, 72 hours and at Days 5 and 7 after implantation. These samples were centrifuged, the plasma harvested, and stored at −70° C. Necropsy included macroscopic examination performed on Day 8 of the observation period.
Treated obese rats (
These data demonstrated that continuous, uniform delivery of exenatide resulted in glucose-lowering together with a potent effect on body weight in treated animals. These results support the use of the DUROS® device for long-term steady state dosing of incretin mimetics, for example, a suspension formulation comprising exenatide, in the treatment of human diabetes.
As is apparent to one of skill in the art, various modification and variations of the above embodiments can be made without departing from the spirit and scope of this invention. Such modifications and variations are within the scope of this invention.
This application is a continuation of U.S. patent application Ser. No. 15/612,581, filed on Jun. 2, 2017, which application is a continuation of U.S. patent application Ser. No. 15/291,523, filed Oct. 12, 2016, now U.S. Pat. No. 9,682,127, which is a continuation of U.S. patent application Ser. No. 14/605,348, filed Jan. 26, 2015, which is a continuation of U.S. patent application Ser. No. 12/927,432, filed Nov. 15, 2010, now U.S. Pat. No. 8,940,316, which is a divisional of U.S. patent application Ser. No. 12/148,896, filed Apr. 22, 2008, now U.S. Pat. No. 8,299,025, which claims the benefit of U.S. Provisional Application Ser. No. 61/072,202, filed Mar. 28, 2008, and U.S. Provisional Application Ser. No. 60/926,005, filed Apr. 23, 2007, and which is a continuation-in-part of U.S. patent application Ser. No. 11/347,562, filed Feb. 3, 2006, now U.S. Pat. No. 8,114,437, which claims the benefit of U.S. Provisional Application No. 60/650,225, filed Feb. 3, 2005. Each of the above-referenced applications is herein incorporated by reference in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2110208 | Eggert | Mar 1938 | A |
| 2168437 | Buercklin | Aug 1939 | A |
| 3025991 | Gillon | Mar 1962 | A |
| 3122162 | Sands | Feb 1964 | A |
| 3523906 | Vrancken et al. | Aug 1970 | A |
| 3625214 | Higuchi | Dec 1971 | A |
| 3632768 | Bergy et al. | Jan 1972 | A |
| 3691090 | Kitajima et al. | Sep 1972 | A |
| D226915 | Huggins | May 1973 | S |
| 3732865 | Higuchi et al. | May 1973 | A |
| 3737337 | Schnoring et al. | Jun 1973 | A |
| 3773919 | Boswell et al. | Nov 1973 | A |
| 3797492 | Place | Mar 1974 | A |
| 3869549 | Geller | Mar 1975 | A |
| 3891570 | Fukushima et al. | Jun 1975 | A |
| D236035 | Ciencewicki | Jul 1975 | S |
| 3960757 | Morishita et al. | Jun 1976 | A |
| 3987790 | Eckenhoff et al. | Oct 1976 | A |
| 3995631 | Higuchi et al. | Dec 1976 | A |
| 3995632 | Nakano et al. | Dec 1976 | A |
| 4008719 | Theeuwes et al. | Feb 1977 | A |
| 4034756 | Higuchi et al. | Jul 1977 | A |
| 4078060 | Benson et al. | Mar 1978 | A |
| 4111201 | Theeuwes | Sep 1978 | A |
| 4111202 | Theeuwes | Sep 1978 | A |
| 4111203 | Theeuwes | Sep 1978 | A |
| 4203439 | Theeuwes | May 1980 | A |
| 4211771 | Witkowski et al. | Jul 1980 | A |
| 4221862 | Naito et al. | Sep 1980 | A |
| 4243030 | Lynch et al. | Jan 1981 | A |
| D258837 | Spranger et al. | Apr 1981 | S |
| 4305927 | Theeuwes et al. | Dec 1981 | A |
| 4310516 | Chang et al. | Jan 1982 | A |
| 4340054 | Michaels | Jul 1982 | A |
| 4350271 | Eckenhoff | Sep 1982 | A |
| 4373527 | Fischell | Feb 1983 | A |
| 4376118 | Daher et al. | Mar 1983 | A |
| 4384975 | Fong | May 1983 | A |
| 4389330 | Tice et al. | Jun 1983 | A |
| 4439196 | Higuchi | Mar 1984 | A |
| 4455143 | Theeuwes et al. | Jun 1984 | A |
| 4455145 | Theeuwes | Jun 1984 | A |
| 4530840 | Tice et al. | Jul 1985 | A |
| 4552561 | Eckenhoff et al. | Nov 1985 | A |
| 4588614 | Lauchenauer | May 1986 | A |
| 4594108 | Greminger, Jr. et al. | Jun 1986 | A |
| 4609374 | Ayer | Sep 1986 | A |
| 4639244 | Rizk et al. | Jan 1987 | A |
| 4655462 | Balsells | Apr 1987 | A |
| 4673405 | Guittard et al. | Jun 1987 | A |
| 4675184 | Hasegawa et al. | Jun 1987 | A |
| 4695623 | Stabinsky | Sep 1987 | A |
| 4727138 | Goeddel et al. | Feb 1988 | A |
| 4734284 | Terada et al. | Mar 1988 | A |
| 4737437 | Gutsell, Jr. et al. | Apr 1988 | A |
| 4743449 | Yoshida et al. | May 1988 | A |
| 4753651 | Eckenhoff | Jun 1988 | A |
| 4762791 | Goeddel et al. | Aug 1988 | A |
| 4765989 | Wong et al. | Aug 1988 | A |
| 4783337 | Wong et al. | Nov 1988 | A |
| 4818517 | Kwee et al. | Apr 1989 | A |
| 4820638 | Swetly et al. | Apr 1989 | A |
| 4826144 | Balsells | May 1989 | A |
| 4830344 | Balsells | May 1989 | A |
| 4840896 | Reddy et al. | Jun 1989 | A |
| 4845196 | Cowling | Jul 1989 | A |
| 4847079 | Kwan | Jul 1989 | A |
| 4851228 | Zentner et al. | Jul 1989 | A |
| 4865845 | Eckenhoff et al. | Sep 1989 | A |
| 4873080 | Brickl et al. | Oct 1989 | A |
| 4874388 | Wong et al. | Oct 1989 | A |
| 4876781 | Balsells | Oct 1989 | A |
| 4885166 | Meyer et al. | Dec 1989 | A |
| 4886668 | Haslam et al. | Dec 1989 | A |
| 4892778 | Theeuwes et al. | Jan 1990 | A |
| 4893795 | Balsells | Jan 1990 | A |
| 4897471 | Stabinsky | Jan 1990 | A |
| 4907788 | Balsells | Mar 1990 | A |
| 4915366 | Balsells | Apr 1990 | A |
| 4915949 | Wong et al. | Apr 1990 | A |
| 4915954 | Ayer et al. | Apr 1990 | A |
| 4917887 | Hauptmann et al. | Apr 1990 | A |
| 4917895 | Lee et al. | Apr 1990 | A |
| 4923805 | Reddy et al. | May 1990 | A |
| 4927687 | Nuwayser | May 1990 | A |
| 4929554 | Goeddel et al. | May 1990 | A |
| 4931285 | Edgren et al. | Jun 1990 | A |
| 4934666 | Balsells | Jun 1990 | A |
| 4940465 | Theeuwes et al. | Jul 1990 | A |
| 4940588 | Sparks et al. | Jul 1990 | A |
| 4952402 | Sparks et al. | Aug 1990 | A |
| 4957119 | de Nijs | Sep 1990 | A |
| 4961253 | Balsells | Oct 1990 | A |
| 4964204 | Balsells | Oct 1990 | A |
| 4969884 | Yum | Nov 1990 | A |
| 4974821 | Balsells | Dec 1990 | A |
| 4976966 | Theeuwes et al. | Dec 1990 | A |
| 5004689 | Fiers et al. | Apr 1991 | A |
| 5006346 | Theeuwes et al. | Apr 1991 | A |
| 5019382 | Cummins, Jr. | May 1991 | A |
| 5019400 | Gombotz et al. | May 1991 | A |
| 5023088 | Wong et al. | Jun 1991 | A |
| 5024842 | Edgren et al. | Jun 1991 | A |
| 5030216 | Theeuwes et al. | Jul 1991 | A |
| 5034229 | Magruder et al. | Jul 1991 | A |
| 5057318 | Magruder et al. | Oct 1991 | A |
| 5059423 | Magruder et al. | Oct 1991 | A |
| 5066436 | Komen et al. | Nov 1991 | A |
| 5071642 | Lahr et al. | Dec 1991 | A |
| 5072070 | Balsells | Dec 1991 | A |
| 5079388 | Balsells | Jan 1992 | A |
| 5091188 | Haynes | Feb 1992 | A |
| 5108078 | Balsells | Apr 1992 | A |
| 5110596 | Magruder et al. | May 1992 | A |
| 5112614 | Magruder et al. | May 1992 | A |
| 5113938 | Clayton | May 1992 | A |
| 5117066 | Balsells | May 1992 | A |
| D326718 | Maxwell | Jun 1992 | S |
| 5118666 | Habener | Jun 1992 | A |
| 5120306 | Gosselin | Jun 1992 | A |
| 5120712 | Habener | Jun 1992 | A |
| 5120832 | Goeddel et al. | Jun 1992 | A |
| 5122128 | Cardinal et al. | Jun 1992 | A |
| 5122377 | Miller | Jun 1992 | A |
| 5126142 | Ayer et al. | Jun 1992 | A |
| 5126147 | Silvestri et al. | Jun 1992 | A |
| 5134244 | Balsells | Jul 1992 | A |
| 5137727 | Eckenhoff | Aug 1992 | A |
| 5151093 | Theeuwes et al. | Sep 1992 | A |
| 5160122 | Balsells | Nov 1992 | A |
| 5160743 | Edgren et al. | Nov 1992 | A |
| 5161806 | Balsells | Nov 1992 | A |
| 5180591 | Margruder et al. | Jan 1993 | A |
| 5190765 | Jao et al. | Mar 1993 | A |
| 5203849 | Balsells | Apr 1993 | A |
| 5204108 | Illum | Apr 1993 | A |
| 5207752 | Sorensen et al. | May 1993 | A |
| 5209746 | Balaban et al. | May 1993 | A |
| 5213809 | Wright et al. | May 1993 | A |
| 5213810 | Steber | May 1993 | A |
| 5219572 | Sivaramakrishnan | Jun 1993 | A |
| 5221278 | Linkwitz et al. | Jun 1993 | A |
| 5223265 | Wong | Jun 1993 | A |
| 5225205 | Orsolini | Jul 1993 | A |
| 5231176 | Goeddel et al. | Jul 1993 | A |
| 5234424 | Yum et al. | Aug 1993 | A |
| 5234692 | Magruder et al. | Aug 1993 | A |
| 5234693 | Magruder et al. | Aug 1993 | A |
| 5234695 | Hobbs et al. | Aug 1993 | A |
| 5252338 | Jao et al. | Oct 1993 | A |
| 5260069 | Chen | Nov 1993 | A |
| 5278151 | Korb et al. | Jan 1994 | A |
| 5279608 | Cherif Cheikh | Jan 1994 | A |
| 5284655 | Bogdansky et al. | Feb 1994 | A |
| 5288501 | Nürnberg et al. | Feb 1994 | A |
| 5288502 | Mcginity et al. | Feb 1994 | A |
| 5290271 | Jernberg | Mar 1994 | A |
| 5300079 | Niezink et al. | Apr 1994 | A |
| 5300302 | Tachon et al. | Apr 1994 | A |
| 5308348 | Balaban et al. | May 1994 | A |
| 5312335 | McKinnon et al. | May 1994 | A |
| 5312389 | Theeuwes et al. | May 1994 | A |
| 5312390 | Wong | May 1994 | A |
| 5318558 | Linkwitz et al. | Jun 1994 | A |
| 5318780 | Viegas et al. | Jun 1994 | A |
| 5320616 | Magndu et al. | Jun 1994 | A |
| 5324280 | Wong et al. | Jun 1994 | A |
| 5336057 | Fukuda et al. | Aug 1994 | A |
| 5336505 | Ng et al. | Aug 1994 | A |
| 5352662 | Brooks et al. | Oct 1994 | A |
| 5368588 | Bettinger | Nov 1994 | A |
| 5368863 | Eckenhoff et al. | Nov 1994 | A |
| 5371089 | Rattan | Dec 1994 | A |
| 5374620 | Clark et al. | Dec 1994 | A |
| 5385738 | Yamahira et al. | Jan 1995 | A |
| 5385887 | Yim et al. | Jan 1995 | A |
| 5407609 | Tice et al. | Apr 1995 | A |
| D358644 | Park | May 1995 | S |
| 5411951 | Mitchell | May 1995 | A |
| 5413572 | Wong et al. | May 1995 | A |
| 5413672 | Hirotsuji et al. | May 1995 | A |
| 5424286 | Eng | Jun 1995 | A |
| 5428024 | Chu et al. | Jun 1995 | A |
| 5429602 | Hauser | Jul 1995 | A |
| 5439688 | Orsolini et al. | Aug 1995 | A |
| 5443459 | Wong et al. | Aug 1995 | A |
| 5445829 | Paradissis et al. | Aug 1995 | A |
| 5456679 | Balaban et al. | Oct 1995 | A |
| 5458888 | Chen | Oct 1995 | A |
| 5464929 | Bezwada et al. | Nov 1995 | A |
| 5472708 | Chen | Dec 1995 | A |
| 5478564 | Wantier et al. | Dec 1995 | A |
| 5486365 | Takado et al. | Jan 1996 | A |
| 5498255 | Wong et al. | Mar 1996 | A |
| 5511355 | Dingler | Apr 1996 | A |
| 5512293 | Landrau et al. | Apr 1996 | A |
| 5512549 | Chen et al. | Apr 1996 | A |
| 5514110 | Teh | May 1996 | A |
| 5529914 | Hubbell et al. | Jun 1996 | A |
| 5531736 | Wong et al. | Jul 1996 | A |
| 5540665 | Mercado et al. | Jul 1996 | A |
| 5540912 | Roorda et al. | Jul 1996 | A |
| 5541172 | Labrie et al. | Jul 1996 | A |
| 5542682 | Goldstein et al. | Aug 1996 | A |
| 5543156 | Roorda et al. | Aug 1996 | A |
| 5545618 | Buckley et al. | Aug 1996 | A |
| 5556642 | Kobayashi et al. | Sep 1996 | A |
| 5557318 | Gabriel | Sep 1996 | A |
| 5571525 | Roorda et al. | Nov 1996 | A |
| 5574008 | Johnson et al. | Nov 1996 | A |
| 5574137 | Gray et al. | Nov 1996 | A |
| 5580578 | Oshlack et al. | Dec 1996 | A |
| 5589167 | Cleland et al. | Dec 1996 | A |
| 5595751 | Bezwada | Jan 1997 | A |
| 5595759 | Wright et al. | Jan 1997 | A |
| 5597579 | Bezwada et al. | Jan 1997 | A |
| 5602010 | Hauptmann et al. | Feb 1997 | A |
| 5605688 | Himmler et al. | Feb 1997 | A |
| 5607687 | Bezwada et al. | Mar 1997 | A |
| 5609885 | Rivera et al. | Mar 1997 | A |
| 5614221 | Fjellstrom | Mar 1997 | A |
| 5614492 | Habener | Mar 1997 | A |
| 5618552 | Bezwada et al. | Apr 1997 | A |
| 5620698 | Bezwada et al. | Apr 1997 | A |
| 5620705 | Dong et al. | Apr 1997 | A |
| 5630796 | Bellhouse et al. | May 1997 | A |
| 5633011 | Dong et al. | May 1997 | A |
| 5635213 | Nystrom et al. | Jun 1997 | A |
| 5639477 | Maruyama et al. | Jun 1997 | A |
| 5639640 | Reddy et al. | Jun 1997 | A |
| 5645850 | Bezwada et al. | Jul 1997 | A |
| 5648088 | Bezwada et al. | Jul 1997 | A |
| 5650173 | Ramstack et al. | Jul 1997 | A |
| 5654008 | Herbert et al. | Aug 1997 | A |
| 5654010 | Johnson et al. | Aug 1997 | A |
| 5656297 | Bernstein et al. | Aug 1997 | A |
| 5656299 | Kino et al. | Aug 1997 | A |
| 5658533 | Orly et al. | Aug 1997 | A |
| 5660847 | Magruder et al. | Aug 1997 | A |
| 5660858 | Parikh et al. | Aug 1997 | A |
| 5660861 | Jao et al. | Aug 1997 | A |
| 5667808 | Johnson et al. | Sep 1997 | A |
| 5668170 | Gyory | Sep 1997 | A |
| 5672549 | Minami et al. | Sep 1997 | A |
| 5676942 | Testa et al. | Oct 1997 | A |
| 5686097 | Taskovich et al. | Nov 1997 | A |
| 5688801 | Mesens et al. | Nov 1997 | A |
| 5690925 | Gray et al. | Nov 1997 | A |
| 5690952 | Magruder et al. | Nov 1997 | A |
| 5698213 | Jamiolkowski et al. | Dec 1997 | A |
| 5700486 | Canal et al. | Dec 1997 | A |
| 5700583 | Jamiolkowski et al. | Dec 1997 | A |
| 5703200 | Bezwada et al. | Dec 1997 | A |
| 5707644 | Illum | Jan 1998 | A |
| 5711967 | Juch | Jan 1998 | A |
| 5713847 | Howard, III et al. | Feb 1998 | A |
| 5718922 | Herrero-Vanreli | Feb 1998 | A |
| 5728088 | Margruder et al. | Mar 1998 | A |
| 5728396 | Peery et al. | Mar 1998 | A |
| 5733572 | Unger et al. | Mar 1998 | A |
| 5736159 | Chen et al. | Apr 1998 | A |
| 5738845 | Imakawa | Apr 1998 | A |
| 5747058 | Tipton et al. | May 1998 | A |
| 5756450 | Hahn et al. | May 1998 | A |
| 5767251 | Reddy et al. | Jun 1998 | A |
| 5770231 | Mesens et al. | Jun 1998 | A |
| 5782396 | Mastri et al. | Jul 1998 | A |
| 5792477 | Rickey et al. | Aug 1998 | A |
| 5795591 | Lee et al. | Aug 1998 | A |
| 5795779 | McCormick et al. | Aug 1998 | A |
| 5807876 | Armistead et al. | Sep 1998 | A |
| 5814323 | Lyle | Sep 1998 | A |
| 5817129 | Labrecque et al. | Oct 1998 | A |
| 5830501 | Dong et al. | Nov 1998 | A |
| 5836935 | Ashton et al. | Nov 1998 | A |
| 5843891 | Sherman | Dec 1998 | A |
| 5844017 | Jamiolkowski et al. | Dec 1998 | A |
| 5851451 | Takechi et al. | Dec 1998 | A |
| 5858746 | Hubbell et al. | Jan 1999 | A |
| 5859150 | Jamiolkowski et al. | Jan 1999 | A |
| 5861166 | Eckenhoff | Jan 1999 | A |
| 5871770 | Margruder et al. | Feb 1999 | A |
| 5871778 | Kino et al. | Feb 1999 | A |
| 5874388 | Hsu | Feb 1999 | A |
| 5876746 | Jona et al. | Mar 1999 | A |
| 5882676 | Lee et al. | Mar 1999 | A |
| D408917 | Hacker | Apr 1999 | S |
| 5904935 | Eckenhoff et al. | May 1999 | A |
| 5906816 | Soos et al. | May 1999 | A |
| 5906830 | Farinas et al. | May 1999 | A |
| 5908621 | Glue et al. | Jun 1999 | A |
| 5916598 | Rickey et al. | Jun 1999 | A |
| 5922253 | Herbert et al. | Jul 1999 | A |
| 5928666 | Farinas et al. | Jul 1999 | A |
| 5932547 | Stevenson et al. | Aug 1999 | A |
| 5938654 | Wong et al. | Aug 1999 | A |
| 5939286 | Johnson et al. | Aug 1999 | A |
| 5942223 | Bazer et al. | Aug 1999 | A |
| 5942253 | Gombotz et al. | Aug 1999 | A |
| 5945126 | Thanoo et al. | Aug 1999 | A |
| 5948430 | Zerbe et al. | Sep 1999 | A |
| 5958909 | Habener | Sep 1999 | A |
| 5962023 | Jamiolkowski et al. | Oct 1999 | A |
| 5965168 | Mesens et al. | Oct 1999 | A |
| 5972370 | Eckenhoff et al. | Oct 1999 | A |
| 5972373 | Yajima et al. | Oct 1999 | A |
| 5976109 | Heruth | Nov 1999 | A |
| 5980945 | Ruiz | Nov 1999 | A |
| 5981719 | Woiszwillo et al. | Nov 1999 | A |
| 5984890 | Gast et al. | Nov 1999 | A |
| 5985305 | Peery et al. | Nov 1999 | A |
| 5989463 | Tracy et al. | Nov 1999 | A |
| 5997527 | Gumucio et al. | Dec 1999 | A |
| 5997902 | Maruyama et al. | Dec 1999 | A |
| 6007805 | Foster et al. | Dec 1999 | A |
| 6017545 | Modi | Jan 2000 | A |
| 6022561 | Carlsson et al. | Feb 2000 | A |
| 6029361 | Newman | Feb 2000 | A |
| 6056718 | Funderburk et al. | May 2000 | A |
| 6060450 | Soos et al. | May 2000 | A |
| 6069133 | Carlo et al. | May 2000 | A |
| 6074660 | Jamiolkowski et al. | Jun 2000 | A |
| 6074673 | Guillen | Jun 2000 | A |
| 6100346 | Jamiolkowski et al. | Aug 2000 | A |
| 6110503 | Rickey et al. | Aug 2000 | A |
| 6113938 | Chen et al. | Sep 2000 | A |
| 6113947 | Cleland et al. | Sep 2000 | A |
| 6120787 | Gustafsson et al. | Sep 2000 | A |
| 6124261 | Stevenson et al. | Sep 2000 | A |
| 6124281 | Lewis et al. | Sep 2000 | A |
| 6127520 | Ueda et al. | Oct 2000 | A |
| 6129761 | Hubbell | Oct 2000 | A |
| 6130200 | Brodbeck et al. | Oct 2000 | A |
| 6132420 | Dionne et al. | Oct 2000 | A |
| 6133249 | Hills | Oct 2000 | A |
| 6133429 | Davis et al. | Oct 2000 | A |
| 6147168 | Jamiolkowski et al. | Nov 2000 | A |
| 6156331 | Peery et al. | Dec 2000 | A |
| 6172046 | Albrecht | Jan 2001 | B1 |
| 6174547 | Dong et al. | Jan 2001 | B1 |
| 6177096 | Zerbe et al. | Jan 2001 | B1 |
| 6183461 | Matsuura et al. | Feb 2001 | B1 |
| 6187095 | Labrecque et al. | Feb 2001 | B1 |
| 6190350 | Davis et al. | Feb 2001 | B1 |
| 6190700 | Okada et al. | Feb 2001 | B1 |
| 6190702 | Takada et al. | Feb 2001 | B1 |
| 6191102 | DiMarchi et al. | Feb 2001 | B1 |
| 6204022 | Johnson et al. | Mar 2001 | B1 |
| 6217893 | Pellet et al. | Apr 2001 | B1 |
| 6217906 | Gumucio et al. | Apr 2001 | B1 |
| 6217908 | Mathiowitz et al. | Apr 2001 | B1 |
| 6218431 | Schoen et al. | Apr 2001 | B1 |
| 6224894 | Jamiolkowski et al. | May 2001 | B1 |
| 6235712 | Stevenson et al. | May 2001 | B1 |
| 6245349 | Yiv et al. | Jun 2001 | B1 |
| 6245357 | Edgren et al. | Jun 2001 | B1 |
| 6248112 | Gambale et al. | Jun 2001 | B1 |
| 6251435 | Jamiolkowski et al. | Jun 2001 | B1 |
| 6258377 | New et al. | Jul 2001 | B1 |
| 6261584 | Peery et al. | Jul 2001 | B1 |
| 6268343 | Knudsen et al. | Jul 2001 | B1 |
| 6270700 | Ignatious | Aug 2001 | B1 |
| 6270787 | Ayer | Aug 2001 | B1 |
| 6277413 | Sankaram | Aug 2001 | B1 |
| 6283949 | Roorda | Sep 2001 | B1 |
| 6284264 | Zerbe et al. | Sep 2001 | B1 |
| 6284725 | Coolidge et al. | Sep 2001 | B1 |
| 6284727 | Kim et al. | Sep 2001 | B1 |
| 6287295 | Chen et al. | Sep 2001 | B1 |
| 6329336 | Bridon et al. | Dec 2001 | B1 |
| 6331311 | Brodbeck et al. | Dec 2001 | B1 |
| 6372218 | Cummins, Jr. | Apr 2002 | B1 |
| 6372256 | Jamiolkowski et al. | Apr 2002 | B2 |
| 6375978 | Kleiner et al. | Apr 2002 | B1 |
| 6395292 | Peery et al. | May 2002 | B2 |
| 6403655 | Bezwada et al. | Jun 2002 | B1 |
| 6419952 | Wong et al. | Jul 2002 | B2 |
| 6433144 | Morris et al. | Aug 2002 | B1 |
| 6436091 | Harper et al. | Aug 2002 | B1 |
| 6447522 | Gambale et al. | Sep 2002 | B2 |
| 6451974 | Hansen | Sep 2002 | B1 |
| 6458385 | Jamiolkowski et al. | Oct 2002 | B2 |
| 6458387 | Scott et al. | Oct 2002 | B1 |
| 6458924 | Knudsen et al. | Oct 2002 | B2 |
| 6461605 | Cutler et al. | Oct 2002 | B1 |
| 6464688 | Harper et al. | Oct 2002 | B1 |
| 6468961 | Brodbeck et al. | Oct 2002 | B1 |
| 6471688 | Harper et al. | Oct 2002 | B1 |
| 6472512 | LaFleur et al. | Oct 2002 | B1 |
| 6485706 | McCoy et al. | Nov 2002 | B1 |
| 6495164 | Ramstack et al. | Dec 2002 | B1 |
| 6506724 | Hiles et al. | Jan 2003 | B1 |
| 6508808 | Carr et al. | Jan 2003 | B1 |
| 6514500 | Bridon et al. | Feb 2003 | B1 |
| 6514517 | Jamilolkowski et al. | Feb 2003 | B2 |
| 6524305 | Peterson et al. | Feb 2003 | B1 |
| 6528093 | Kamei et al. | Mar 2003 | B1 |
| 6528486 | Larsen et al. | Mar 2003 | B1 |
| 6541021 | Johnson et al. | Apr 2003 | B1 |
| 6544252 | Theeuwes et al. | Apr 2003 | B1 |
| 6551613 | Dong et al. | Apr 2003 | B1 |
| 6569420 | Chen et al. | May 2003 | B2 |
| 6572890 | Faour et al. | Jun 2003 | B2 |
| 6579851 | Goeke et al. | Jun 2003 | B2 |
| 6592887 | Zerbe et al. | Jul 2003 | B2 |
| 6593295 | Bridon et al. | Jul 2003 | B2 |
| 6635268 | Peery et al. | Oct 2003 | B2 |
| 6667061 | Ramstack et al. | Dec 2003 | B2 |
| 6670368 | Breault et al. | Dec 2003 | B1 |
| 6673767 | Brodbeck et al. | Jan 2004 | B1 |
| 6682522 | Carr et al. | Jan 2004 | B2 |
| 6703225 | Kojima et al. | Mar 2004 | B1 |
| 6703359 | Young et al. | Mar 2004 | B1 |
| 6706689 | Coolidge et al. | Mar 2004 | B2 |
| 6709671 | Zerbe et al. | Mar 2004 | B2 |
| 6720407 | Hughes et al. | Apr 2004 | B1 |
| 6730328 | Maskiwicz et al. | May 2004 | B2 |
| 6767887 | Hoffmann et al. | Jul 2004 | B1 |
| 6821949 | Bridon et al. | Nov 2004 | B2 |
| 6833256 | Pontzer et al. | Dec 2004 | B1 |
| 6835194 | Johnson et al. | Dec 2004 | B2 |
| 6840931 | Peterson et al. | Jan 2005 | B2 |
| 6849708 | Habener | Feb 2005 | B1 |
| 6849714 | Bridon et al. | Feb 2005 | B1 |
| 6858576 | Young et al. | Feb 2005 | B1 |
| 6872700 | Young et al. | Mar 2005 | B1 |
| 6875748 | Manthorpe et al. | Apr 2005 | B2 |
| 6887470 | Bridon et al. | May 2005 | B1 |
| 6887849 | Bridon et al. | May 2005 | B2 |
| 6899887 | Ayer | May 2005 | B2 |
| 6899898 | Albayrak | May 2005 | B2 |
| 6902744 | Kolterman et al. | Jun 2005 | B1 |
| 6903186 | Dong | Jun 2005 | B1 |
| 6913767 | Cleland et al. | Jul 2005 | B1 |
| 6923800 | Chen et al. | Aug 2005 | B2 |
| 6924264 | Prickett et al. | Aug 2005 | B1 |
| 6939556 | Lautenbach | Sep 2005 | B2 |
| 6956026 | Beeley et al. | Oct 2005 | B2 |
| 6969702 | Bertilsson et al. | Nov 2005 | B2 |
| 6976981 | Ayer | Dec 2005 | B2 |
| 6989366 | Beeley et al. | Jan 2006 | B2 |
| 6992065 | Okumu | Jan 2006 | B2 |
| 6997922 | Theeuwes et al. | Feb 2006 | B2 |
| 7014636 | Gilbert | Mar 2006 | B2 |
| 7022674 | DeFelippis et al. | Apr 2006 | B2 |
| 7041646 | Pan et al. | May 2006 | B2 |
| 7074423 | Fereira et al. | Jul 2006 | B2 |
| 7084243 | Glaesner et al. | Aug 2006 | B2 |
| 7101567 | Sano et al. | Sep 2006 | B1 |
| 7101843 | Glaesner et al. | Sep 2006 | B2 |
| 7112335 | Lautenbach | Sep 2006 | B2 |
| 7115569 | Beeley et al. | Oct 2006 | B2 |
| 7138375 | Beeley et al. | Nov 2006 | B2 |
| 7138486 | Habener et al. | Nov 2006 | B2 |
| 7141547 | Rosen et al. | Nov 2006 | B2 |
| 7144863 | DeFelippis et al. | Dec 2006 | B2 |
| 7153825 | Young et al. | Dec 2006 | B2 |
| 7157555 | Beeley et al. | Jan 2007 | B1 |
| 7163688 | Peery et al. | Jan 2007 | B2 |
| 7163697 | Hanes et al. | Jan 2007 | B2 |
| 7199217 | DiMarchi et al. | Apr 2007 | B2 |
| 7205409 | Pei et al. | Apr 2007 | B2 |
| 7207982 | Dionne et al. | Apr 2007 | B2 |
| 7241457 | Chen et al. | Jul 2007 | B2 |
| 7258869 | Berry et al. | Aug 2007 | B1 |
| 7297761 | Beeley et al. | Nov 2007 | B2 |
| 7316680 | Gilbert | Jan 2008 | B2 |
| 7393827 | Nadler | Jul 2008 | B2 |
| 7407499 | Trautman | Aug 2008 | B2 |
| 7442682 | Kitaura et al. | Oct 2008 | B2 |
| 7456254 | Wright et al. | Nov 2008 | B2 |
| 7459432 | Cowley et al. | Dec 2008 | B2 |
| 7521423 | Young et al. | Apr 2009 | B2 |
| 7563871 | Wright et al. | Jul 2009 | B2 |
| 7589169 | Bolotin | Sep 2009 | B2 |
| 7612176 | Wright et al. | Nov 2009 | B2 |
| 7635463 | Bolotin et al. | Dec 2009 | B2 |
| 7655254 | Dennis et al. | Feb 2010 | B2 |
| 7655257 | Peery et al. | Feb 2010 | B2 |
| 7666835 | Bloom et al. | Feb 2010 | B2 |
| 7682356 | Alessi et al. | Mar 2010 | B2 |
| 7727519 | Moran | Jun 2010 | B2 |
| 7731947 | Eliaz et al. | Jun 2010 | B2 |
| 7736665 | Patel et al. | Jun 2010 | B2 |
| 7741269 | Young et al. | Jun 2010 | B2 |
| 7790140 | Bolotin | Sep 2010 | B2 |
| 7825091 | Bloom et al. | Nov 2010 | B2 |
| 7829109 | Chen et al. | Nov 2010 | B2 |
| 7833543 | Gibson et al. | Nov 2010 | B2 |
| 7879028 | Alessi et al. | Feb 2011 | B2 |
| 7879794 | Weyer et al. | Feb 2011 | B2 |
| 7919109 | Berry et al. | Apr 2011 | B2 |
| 7928065 | Young et al. | Apr 2011 | B2 |
| 7959938 | Rohloff et al. | Jun 2011 | B2 |
| 7964183 | Eliaz et al. | Jun 2011 | B2 |
| 8039432 | Bridon et al. | Oct 2011 | B2 |
| 8048438 | Berry et al. | Nov 2011 | B2 |
| 8052996 | Lautenbach et al. | Nov 2011 | B2 |
| 8058233 | Cowley et al. | Nov 2011 | B2 |
| 8101576 | Bloom | Jan 2012 | B2 |
| 8114430 | Rohloff et al. | Feb 2012 | B2 |
| 8114437 | Rohloff et al. | Feb 2012 | B2 |
| 8158150 | Lautenbach et al. | Apr 2012 | B2 |
| 8173150 | Berry et al. | May 2012 | B2 |
| 8202836 | Moore et al. | Jun 2012 | B2 |
| 8206745 | Rohloff et al. | Jun 2012 | B2 |
| 8211467 | Rohloff et al. | Jul 2012 | B2 |
| 8217001 | Cowley et al. | Jul 2012 | B2 |
| 8231859 | Bolotin et al. | Jul 2012 | B2 |
| 8257682 | Bolotin et al. | Sep 2012 | B2 |
| 8257691 | Eliaz et al. | Sep 2012 | B2 |
| 8262667 | Silver et al. | Sep 2012 | B1 |
| 8263545 | Levy et al. | Sep 2012 | B2 |
| 8263736 | Berry | Sep 2012 | B2 |
| 8268341 | Berry | Sep 2012 | B2 |
| 8273365 | Lautenbach et al. | Sep 2012 | B2 |
| 8273713 | Pittner et al. | Sep 2012 | B2 |
| D669589 | Delaey | Oct 2012 | S |
| 8277776 | Bolotin et al. | Oct 2012 | B2 |
| 8278267 | Weyer et al. | Oct 2012 | B2 |
| 8288338 | Young et al. | Oct 2012 | B2 |
| 8298561 | Alessi et al. | Oct 2012 | B2 |
| 8299025 | Alessi et al. | Oct 2012 | B2 |
| 8343140 | Alessi et al. | Jan 2013 | B2 |
| 8367095 | Lautenbach et al. | Feb 2013 | B2 |
| 8372424 | Berry et al. | Feb 2013 | B2 |
| 8398967 | Eliaz et al. | Mar 2013 | B2 |
| 8440226 | Rohloff et al. | May 2013 | B2 |
| 8460694 | Rohloff et al. | Jun 2013 | B2 |
| 8470353 | Lautenbach et al. | Jun 2013 | B2 |
| 8801700 | Alessi et al. | Aug 2014 | B2 |
| 8865202 | Zerbe et al. | Oct 2014 | B2 |
| 8888745 | Van Der Graaf et al. | Nov 2014 | B2 |
| 8926595 | Alessi et al. | Jan 2015 | B2 |
| 8940316 | Alessi et al. | Jan 2015 | B2 |
| 8992961 | Berry et al. | Mar 2015 | B2 |
| 8992962 | Lautenbach et al. | Mar 2015 | B2 |
| 9044209 | Dayton et al. | Jun 2015 | B2 |
| 9078900 | Kuzma et al. | Jul 2015 | B2 |
| 9095553 | Rohloff et al. | Aug 2015 | B2 |
| 9332995 | Russo | May 2016 | B2 |
| 9526763 | Rohloff et al. | Dec 2016 | B2 |
| 9539200 | Lautenbach | Jan 2017 | B2 |
| 9572889 | Alessi et al. | Feb 2017 | B2 |
| 9682127 | Alessi et al. | Jun 2017 | B2 |
| 20010012511 | Bezwada et al. | Aug 2001 | A1 |
| 20010021377 | Jamiolkowski et al. | Sep 2001 | A1 |
| 20010021822 | Ayer | Sep 2001 | A1 |
| 20010022974 | Ayer | Sep 2001 | A1 |
| 20010026793 | Jamiolkowski et al. | Oct 2001 | A1 |
| 20010027311 | Chen et al. | Oct 2001 | A1 |
| 20010031790 | Beisswenger | Nov 2001 | A1 |
| 20010036472 | Wong et al. | Nov 2001 | A1 |
| 20010040326 | Balczun | Nov 2001 | A1 |
| 20020001631 | Okumu | Jan 2002 | A1 |
| 20020004481 | Cleland et al. | Jan 2002 | A1 |
| 20020012818 | Ruppi et al. | Jan 2002 | A1 |
| 20020034532 | Brodbeck et al. | Mar 2002 | A1 |
| 20020037309 | Jaworowicz et al. | Mar 2002 | A1 |
| 20020048600 | Bhatt et al. | Apr 2002 | A1 |
| 20020136848 | Yoshii et al. | Sep 2002 | A1 |
| 20020137666 | Beeley et al. | Sep 2002 | A1 |
| 20020141985 | Pittner et al. | Oct 2002 | A1 |
| 20020197185 | Jamiolkowski et al. | Dec 2002 | A1 |
| 20020197235 | Moran | Dec 2002 | A1 |
| 20030032947 | Harper et al. | Feb 2003 | A1 |
| 20030044467 | Brodbeck et al. | Mar 2003 | A1 |
| 20030045454 | Okumu et al. | Mar 2003 | A1 |
| 20030059376 | Libbey et al. | Mar 2003 | A1 |
| 20030060425 | Ahlem et al. | Mar 2003 | A1 |
| 20030097121 | Jolly et al. | May 2003 | A1 |
| 20030104063 | Babcock et al. | Jun 2003 | A1 |
| 20030108608 | Laridon et al. | Jun 2003 | A1 |
| 20030108609 | Berry et al. | Jun 2003 | A1 |
| 20030113380 | Ramstack et al. | Jun 2003 | A1 |
| 20030114837 | Peterson et al. | Jun 2003 | A1 |
| 20030118660 | Rickey et al. | Jun 2003 | A1 |
| 20030138403 | Drustrup | Jul 2003 | A1 |
| 20030138491 | Tracy et al. | Jul 2003 | A1 |
| 20030157178 | Chen et al. | Aug 2003 | A1 |
| 20030170289 | Chen et al. | Sep 2003 | A1 |
| 20030180364 | Chen et al. | Sep 2003 | A1 |
| 20030186858 | Arentsen | Oct 2003 | A1 |
| 20030191099 | Bohlmann et al. | Oct 2003 | A1 |
| 20030211974 | Brodbeck et al. | Nov 2003 | A1 |
| 20030215515 | Truong-Le et al. | Nov 2003 | A1 |
| 20040001689 | Goldsmith et al. | Jan 2004 | A1 |
| 20040001889 | Chen et al. | Jan 2004 | A1 |
| 20040002442 | Pan et al. | Jan 2004 | A1 |
| 20040022859 | Chen et al. | Feb 2004 | A1 |
| 20040024068 | Levy et al. | Feb 2004 | A1 |
| 20040024069 | Chen et al. | Feb 2004 | A1 |
| 20040029784 | Hathaway | Feb 2004 | A1 |
| 20040039376 | Peery et al. | Feb 2004 | A1 |
| 20040097906 | Fereira et al. | May 2004 | A1 |
| 20040101557 | Gibson et al. | May 2004 | A1 |
| 20040102762 | Gilbert | May 2004 | A1 |
| 20040115236 | Chan et al. | Jun 2004 | A1 |
| 20040142867 | Oi et al. | Jul 2004 | A1 |
| 20040142902 | Struijker-Boudier | Jul 2004 | A1 |
| 20040151753 | Chen et al. | Aug 2004 | A1 |
| 20040157951 | Wolf | Aug 2004 | A1 |
| 20040198654 | Glaesner et al. | Oct 2004 | A1 |
| 20040209801 | Brand et al. | Oct 2004 | A1 |
| 20040224903 | Berry et al. | Nov 2004 | A1 |
| 20040225113 | LaFleur et al. | Nov 2004 | A1 |
| 20040243106 | Ayer | Dec 2004 | A1 |
| 20040265273 | Li et al. | Dec 2004 | A1 |
| 20040266683 | Hathaway et al. | Dec 2004 | A1 |
| 20040266692 | Young et al. | Dec 2004 | A1 |
| 20050004557 | Russell | Jan 2005 | A1 |
| 20050008661 | Fereira et al. | Jan 2005 | A1 |
| 20050009742 | Bertilsson et al. | Jan 2005 | A1 |
| 20050010196 | Fereira et al. | Jan 2005 | A1 |
| 20050010942 | Kim et al. | Jan 2005 | A1 |
| 20050070883 | Brown et al. | Mar 2005 | A1 |
| 20050070927 | Feinberg | Mar 2005 | A1 |
| 20050079200 | Rathenow et al. | Apr 2005 | A1 |
| 20050079202 | Chen et al. | Apr 2005 | A1 |
| 20050095284 | Trautman | May 2005 | A1 |
| 20050101943 | Ayer et al. | May 2005 | A1 |
| 20050106214 | Chen | May 2005 | A1 |
| 20050112188 | Eliaz et al. | May 2005 | A1 |
| 20050118206 | Luk et al. | Jun 2005 | A1 |
| 20050118221 | Blakely et al. | Jun 2005 | A1 |
| 20050131386 | Freeman et al. | Jun 2005 | A1 |
| 20050131389 | Peterson et al. | Jun 2005 | A1 |
| 20050175701 | Pan et al. | Aug 2005 | A1 |
| 20050201980 | Moran | Sep 2005 | A1 |
| 20050215475 | Ong et al. | Sep 2005 | A1 |
| 20050216087 | Zucherman, Jr. et al. | Sep 2005 | A1 |
| 20050266087 | Junnarkar et al. | Dec 2005 | A1 |
| 20050271702 | Wright et al. | Dec 2005 | A1 |
| 20050276856 | Fereira et al. | Dec 2005 | A1 |
| 20050281879 | Chen et al. | Dec 2005 | A1 |
| 20060013879 | Brodbeck et al. | Jan 2006 | A9 |
| 20060014678 | Cowley et al. | Jan 2006 | A1 |
| 20060030526 | Liu et al. | Feb 2006 | A1 |
| 20060069029 | Kolterman et al. | Mar 2006 | A1 |
| 20060084604 | Kitaura et al. | Apr 2006 | A1 |
| 20060084922 | Botha | Apr 2006 | A1 |
| 20060094652 | Levy et al. | May 2006 | A1 |
| 20060106399 | Taras et al. | May 2006 | A1 |
| 20060141040 | Chen et al. | Jun 2006 | A1 |
| 20060142234 | Chen et al. | Jun 2006 | A1 |
| 20060160736 | Nadler | Jul 2006 | A1 |
| 20060178304 | Juul-Mortensen et al. | Aug 2006 | A1 |
| 20060193918 | Rohloff et al. | Aug 2006 | A1 |
| 20060216242 | Rohloff et al. | Sep 2006 | A1 |
| 20060224145 | Gills | Oct 2006 | A1 |
| 20060233841 | Brodbeck et al. | Oct 2006 | A1 |
| 20060024613 | Rohloff et al. | Nov 2006 | A1 |
| 20060251618 | Dennis et al. | Nov 2006 | A1 |
| 20060263433 | Ayer et al. | Nov 2006 | A1 |
| 20060264890 | Moberg et al. | Nov 2006 | A1 |
| 20060280795 | Penhasi et al. | Dec 2006 | A1 |
| 20060293232 | Levy et al. | Dec 2006 | A1 |
| 20070027105 | Junnarkar et al. | Feb 2007 | A1 |
| 20070149011 | Kent et al. | Jun 2007 | A1 |
| 20070166352 | Wright et al. | Jul 2007 | A1 |
| 20070020795 | Bridon et al. | Sep 2007 | A1 |
| 20070248572 | Moran et al. | Oct 2007 | A1 |
| 20070281024 | Lautenbach et al. | Dec 2007 | A1 |
| 20080020016 | Li et al. | Jan 2008 | A1 |
| 20080038316 | Wong et al. | Feb 2008 | A1 |
| 20080064636 | Bloom et al. | Mar 2008 | A1 |
| 20080065090 | Scribner et al. | Mar 2008 | A1 |
| 20080091176 | Alessi et al. | Apr 2008 | A1 |
| 20080110515 | Angelosanto et al. | May 2008 | A1 |
| 20080112994 | Junnarkar et al. | May 2008 | A1 |
| 20080200383 | Jennings et al. | Aug 2008 | A1 |
| 20080207512 | Roth et al. | Aug 2008 | A1 |
| 20080226625 | Berry et al. | Sep 2008 | A1 |
| 20080226689 | Berry et al. | Sep 2008 | A1 |
| 20080260838 | Hokenson et al. | Oct 2008 | A1 |
| 20080260840 | Alessi et al. | Oct 2008 | A1 |
| 20080269725 | Deem et al. | Oct 2008 | A1 |
| 20080312157 | Levy et al. | Dec 2008 | A1 |
| 20090022727 | Houston et al. | Jan 2009 | A1 |
| 20090036364 | Levy et al. | Feb 2009 | A1 |
| 20090042781 | Petersen et al. | Feb 2009 | A1 |
| 20090074734 | Rottiers | Mar 2009 | A1 |
| 20090087408 | Berry et al. | Apr 2009 | A1 |
| 20090156474 | Roth et al. | Jun 2009 | A1 |
| 20090163447 | Maggio | Jun 2009 | A1 |
| 20090186817 | Ghosh et al. | Jul 2009 | A1 |
| 20090202481 | Li et al. | Aug 2009 | A1 |
| 20090202608 | Alessi et al. | Aug 2009 | A1 |
| 20090209460 | Young et al. | Aug 2009 | A1 |
| 20090210019 | Kim et al. | Aug 2009 | A1 |
| 20090215694 | Kolterman et al. | Aug 2009 | A1 |
| 20090234392 | Dziedzic | Sep 2009 | A1 |
| 20090247463 | Wright et al. | Oct 2009 | A1 |
| 20090254143 | Tweden et al. | Oct 2009 | A1 |
| 20090286723 | Levy et al. | Nov 2009 | A1 |
| 20090312246 | Baron et al. | Dec 2009 | A1 |
| 20100092566 | Alessi et al. | Apr 2010 | A1 |
| 20100105627 | Salama et al. | Apr 2010 | A1 |
| 20100144621 | Kim et al. | Jun 2010 | A1 |
| 20100185184 | Alessi et al. | Jul 2010 | A1 |
| 20100297209 | Rohloff et al. | Nov 2010 | A1 |
| 20100298840 | Schwartz | Nov 2010 | A1 |
| 20110076317 | Alessi et al. | Mar 2011 | A1 |
| 20110091527 | Moonen et al. | Apr 2011 | A1 |
| 20110104111 | Rohloff et al. | May 2011 | A1 |
| 20110152181 | Alsina-Femandez et al. | Jun 2011 | A1 |
| 20110152182 | Alsina-Femandez et al. | Jun 2011 | A1 |
| 20110160708 | Berry et al. | Jun 2011 | A1 |
| 20110166554 | Alessi et al. | Jul 2011 | A1 |
| 20110264077 | Rohloff et al. | Oct 2011 | A1 |
| 20110306549 | Tatarkiewicz et al. | Dec 2011 | A1 |
| 20120208755 | Leung | Aug 2012 | A1 |
| 20130030417 | Alessi | Jan 2013 | A1 |
| 20130034210 | Rohloff et al. | Feb 2013 | A1 |
| 20130052237 | Eliaz et al. | Feb 2013 | A1 |
| 20140058425 | Porat | Feb 2014 | A1 |
| 20140121741 | Bennett et al. | May 2014 | A1 |
| 20140257272 | Clark, III et al. | Sep 2014 | A1 |
| 20140378900 | Alessi et al. | Dec 2014 | A1 |
| 20150001118 | Selepack et al. | Jan 2015 | A1 |
| 20150057227 | Leung | Feb 2015 | A1 |
| 20150133791 | Sato et al. | May 2015 | A1 |
| 20150231062 | Lautenbach et al. | Aug 2015 | A1 |
| 20150231256 | Berry et al. | Aug 2015 | A1 |
| 20150297509 | Schwarz | Oct 2015 | A1 |
| 20160000225 | Alessi et al. | Jan 2016 | A1 |
| 20160030337 | Kuzma et al. | Feb 2016 | A1 |
| 20160354115 | Smith et al. | Dec 2016 | A1 |
| 20160354305 | Alessi et al. | Dec 2016 | A1 |
| 20170056476 | Rohloff et al. | Mar 2017 | A1 |
| 20170079906 | Alessi et al. | Mar 2017 | A1 |
| 20170119854 | Alessi et al. | May 2017 | A1 |
| 20170119855 | Berry et al. | May 2017 | A1 |
| 20170181964 | Lautenbach et al. | Jun 2017 | A1 |
| 20170252409 | Leung | Sep 2017 | A1 |
| 20170319470 | Eliaz et al. | Nov 2017 | A1 |
| 20170319662 | Berry et al. | Nov 2017 | A1 |
| Number | Date | Country |
|---|---|---|
| 0052510 | May 1982 | EP |
| 0079405 | May 1983 | EP |
| 0254394 | Jan 1988 | EP |
| 0295411 | Dec 1988 | EP |
| 0302582 | Feb 1989 | EP |
| 0368339 | May 1990 | EP |
| 0373867 | Jun 1990 | EP |
| 0431942 | Jun 1991 | EP |
| 0486959 | May 1992 | EP |
| 0521586 | Jan 1993 | EP |
| 0596161 | May 1994 | EP |
| 0379147 | Sep 1994 | EP |
| 0627231 | Dec 1994 | EP |
| 0729747 | May 1997 | EP |
| 0771817 | May 1997 | EP |
| 0841359 | May 1998 | EP |
| 0767689 | Jun 1999 | EP |
| 1046399 | Oct 2000 | EP |
| 1084703 | Mar 2001 | EP |
| 1300129 | Apr 2003 | EP |
| 1300173 | Apr 2003 | EP |
| 1600187 | Jan 2009 | EP |
| 2133073 | Dec 2009 | EP |
| 2020990 | Sep 2010 | EP |
| 640907 | Jul 1928 | FR |
| 1049104 | Nov 1966 | GB |
| 1518683 | Jul 1978 | GB |
| 2501400 | Oct 2013 | GB |
| H02124814 | May 1990 | JP |
| H07196479 | Aug 1995 | JP |
| 9241153 | Sep 1997 | JP |
| 11-100353 | Apr 1999 | JP |
| 2006213727 | Aug 2006 | JP |
| 10-0183058 | May 1999 | KR |
| 10-2004-0055813 | Jun 2004 | KR |
| 9100160 | Aug 1992 | NL |
| 592113 | Aug 2012 | NZ |
| 200634060 | Oct 2006 | TW |
| WO1989003678 | May 1989 | WO |
| WO1990013285 | Nov 1990 | WO |
| WO1990013361 | Nov 1990 | WO |
| WO1990013780 | Nov 1990 | WO |
| WO 9107160 | May 1991 | WO |
| WO1992019241 | Nov 1992 | WO |
| WO 9306819 | Apr 1993 | WO |
| WO 9306821 | Apr 1993 | WO |
| WO 93008832 | May 1993 | WO |
| WO 9309763 | May 1993 | WO |
| WO 9323083 | Nov 1993 | WO |
| WO 9409743 | May 1994 | WO |
| WO1994010982 | May 1994 | WO |
| WO 9421262 | Sep 1994 | WO |
| WO 9501167 | Jan 1995 | WO |
| WO 9509006 | Apr 1995 | WO |
| WO 9509007 | Apr 1995 | WO |
| WO1995013799 | May 1995 | WO |
| WO 9534285 | Dec 1995 | WO |
| WO 96001134 | Jan 1996 | WO |
| WO 96003116 | Feb 1996 | WO |
| WO1996036317 | Nov 1996 | WO |
| WO 9639142 | Dec 1996 | WO |
| WO 9640049 | Dec 1996 | WO |
| WO 9640139 | Dec 1996 | WO |
| WO 9640355 | Dec 1996 | WO |
| WO1996040049 | Dec 1996 | WO |
| WO 9715289 | May 1997 | WO |
| WO 9715296 | May 1997 | WO |
| WO 9728181 | Aug 1997 | WO |
| WO1997031943 | Sep 1997 | WO |
| WO1997044039 | Nov 1997 | WO |
| WO 9746204 | Dec 1997 | WO |
| WO 9747339 | Dec 1997 | WO |
| WO 9800152 | Jan 1998 | WO |
| WO 9800157 | Jan 1998 | WO |
| WO 9800158 | Jan 1998 | WO |
| WO 9802169 | Jan 1998 | WO |
| WO1997041837 | Feb 1998 | WO |
| WO1998007412 | Feb 1998 | WO |
| WO 9816250 | Apr 1998 | WO |
| WO 9817315 | Apr 1998 | WO |
| WO 9820930 | May 1998 | WO |
| WO 9827960 | Jul 1998 | WO |
| WO 98027962 | Jul 1998 | WO |
| WO 9827963 | Jul 1998 | WO |
| WO 98030231 | Jul 1998 | WO |
| WO 9832463 | Jul 1998 | WO |
| WO1998030231 | Jul 1998 | WO |
| WO 9842317 | Oct 1998 | WO |
| WO 9847487 | Oct 1998 | WO |
| WO 9851282 | Nov 1998 | WO |
| WO 9903453 | Jan 1999 | WO |
| WO 9904767 | Feb 1999 | WO |
| WO 99004768 | Feb 1999 | WO |
| WO1999012549 | Mar 1999 | WO |
| WO 9916419 | Apr 1999 | WO |
| WO 99025728 | May 1999 | WO |
| WO 9929306 | Jun 1999 | WO |
| WO 99033446 | Jul 1999 | WO |
| WO 9933449 | Jul 1999 | WO |
| WO 9939700 | Aug 1999 | WO |
| WO 99040788 | Aug 1999 | WO |
| WO 99044659 | Sep 1999 | WO |
| WO 990625 01 | Dec 1999 | WO |
| WO 99064061 | Dec 1999 | WO |
| WO 00013663 | Mar 2000 | WO |
| WO 00029206 | May 2000 | WO |
| WO 00038652 | Jul 2000 | WO |
| WO 00039280 | Jul 2000 | WO |
| WO 00040273 | Jul 2000 | WO |
| WO 00041548 | Jul 2000 | WO |
| WO 00045790 | Aug 2000 | WO |
| WO 00054745 | Sep 2000 | WO |
| WO2000059476 | Oct 2000 | WO |
| WO 00066138 | Nov 2000 | WO |
| WO 00067728 | Nov 2000 | WO |
| WO2000066087 | Nov 2000 | WO |
| WO2001019345 | Mar 2001 | WO |
| WO2001028525 | Apr 2001 | WO |
| WO 01043528 | Jun 2001 | WO |
| WO 01051041 | Jul 2001 | WO |
| WO 0178683 | Oct 2001 | WO |
| WO 02028366 | Apr 2002 | WO |
| WO 02036072 | May 2002 | WO |
| WO 02043800 | Jun 2002 | WO |
| WO 02045752 | Jun 2002 | WO |
| WO 0247716 | Jun 2002 | WO |
| WO 02067895 | Sep 2002 | WO |
| WO 02069983 | Sep 2002 | WO |
| WO 0276344 | Oct 2002 | WO |
| WO 02085428 | Oct 2002 | WO |
| WO 03000230 | Jan 2003 | WO |
| WO 03007981 | Jan 2003 | WO |
| WO 03011892 | Feb 2003 | WO |
| WO 03024357 | Mar 2003 | WO |
| WO 03024503 | Mar 2003 | WO |
| WO2003020245 | Mar 2003 | WO |
| WO 03030923 | Apr 2003 | WO |
| WO 03041684 | May 2003 | WO |
| WO 03041757 | May 2003 | WO |
| WO 03053400 | Jul 2003 | WO |
| WO2003066585 | Aug 2003 | WO |
| WO 03072113 | Sep 2003 | WO |
| WO 03072133 | Sep 2003 | WO |
| WO 04002565 | Jan 2004 | WO |
| WO2004034975 | Apr 2004 | WO |
| WO2004035754 | Apr 2004 | WO |
| WO2004035762 | Apr 2004 | WO |
| WO2004036186 | Apr 2004 | WO |
| WO 04052336 | Jun 2004 | WO |
| WO 04056338 | Jul 2004 | WO |
| WO 04089335 | Oct 2004 | WO |
| WO2004103342 | Dec 2004 | WO |
| WO 05048930 | Jun 2005 | WO |
| WO 05048952 | Jun 2005 | WO |
| WO 05102293 | Nov 2005 | WO |
| WO2005102293 | Nov 2005 | WO |
| WO2005110425 | Nov 2005 | WO |
| WO 06017772 | Feb 2006 | WO |
| WO 06023526 | Mar 2006 | WO |
| WO 06081279 | Aug 2006 | WO |
| WO 06083761 | Aug 2006 | WO |
| WO 06084139 | Aug 2006 | WO |
| WO 06086727 | Aug 2006 | WO |
| WO 06101815 | Sep 2006 | WO |
| WO 06111169 | Oct 2006 | WO |
| WO2006131730 | Dec 2006 | WO |
| WO 07024700 | Mar 2007 | WO |
| WO 07056681 | May 2007 | WO |
| WO 07075534 | Jul 2007 | WO |
| WO 07084460 | Jul 2007 | WO |
| WO 07133778 | Nov 2007 | WO |
| WO 07140416 | Dec 2007 | WO |
| WO 08021133 | Feb 2008 | WO |
| WO2008041245 | Apr 2008 | WO |
| WO 08061355 | May 2008 | WO |
| WO 08133908 | Nov 2008 | WO |
| WO 08134425 | Nov 2008 | WO |
| WO 09109927 | Sep 2009 | WO |
| WO2009143285 | Nov 2009 | WO |
| WO 2013004983 | Jan 2013 | WO |
| Entry |
|---|
| Akers, et al., “Formulation Design and Development of Parenteral Suspensions,” Journal of Parenteral Science & Technology, 41(3): 88-96 (1987). |
| Alonso, et al., “Determinants of Release Rate of Tetanus Vaccine from Polyester Microspheres,” Pharmaceutical Research, 10(7):945-953 (1993). |
| Beck, et al., “Poly(dl-lactide-co-glycolide)/norethisterone microcapsules: An injectable biodegradable contraceptive,” Biology of Reproduction, 28(1): 186-195 (1983). |
| Bodmeier and McGinity, “Solvent selection in the preparation of poly(dl-lactide) microspheres prepared by the solvent evaporation method,” International Journal of Pharmaceutics, 43(1-2): 179-186 (Apr. 1988). |
| Cha and Pitt, “A one-week subdermal delivery system for l-methadone based on biodegradable microcapsules,” Journal of Controlled Release, 7: 69-78 (1988). |
| Cha and Pitt, “The acceleration of degradation-controlled drug delivery from polyester microspheres,” Journal of Controlled Release, 8: 259-265 (1989). |
| Cohen, et al., “Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres,” Pharmaceutical Research, 8(6): 713-720 (1991). |
| Conti, et al., “Use of polylactic acid for the preparation of microparticulate drug delivery systems,” Journal of Microencapsulation, 9(2): 153-166 (1992). |
| Hodgman, et al., Eds., Handbook of Chemistry and Physics, 35th Edition, 1024-1025 (1953). |
| Jalil and Nixon, “Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: Problems associated with preparative techniques and release properties,” Journal of Microencapsulation, 7(3): 297-325 (Jul.-Sep. 1990). |
| Lee and Timasheff, “The stabilization of proteins by sucrose,” J. Biological Chem., 256(14): 7193-7201 (Jul. 1981). |
| Li, et al., “Prediction of solvent removal profile and effect on properties for peptide-loaded PLGA microspheres prepared by solvent extraction/evaporation method,” Journal of Controlled Release, 37: 199-214 (1995). |
| Maa and Hsu, “Liquid-liquid emulsification by static mixers for use in microencapsulation,” Journal of Microencapsulation, 13(4): 419-433 (Jul.-Aug. 1996). |
| Maulding, et al., “Biodegradable microcapsules: Acceleration of polymeric excipient hydrolytic rate by incorporation of a basic medicament,” Journal of Controlled Release, 3: 103-117 (1986). |
| Mehta, et al.,“Peptide containing microspheres from low molecular weight and hydrophilic poly(d.l-lactide-co-glycolide),” Journal of Controlled Release, 41: 249-257 (1996). |
| Sah, et al., “A novel method of preparing PLGA microcapsules utilizing methylethyl ketone,” Pharmaceutical Research, 13(3): 360-367 (1996). |
| Sato, et al., “Porous biodegradable microspheres for controlled drug delivery. I. Assessment of processing conditions and solvent removal techniques,” Pharmaceutical Research, 5(1): 21-30 (1988). |
| Szayna, et al., “Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats,” Endocrinology, 141(6): 1936-1941 (2000). |
| Thomasin, et al., “A contribution to overcoming the problem of residual solvents in biodegradable microspheres prepared by coacervation,” Eur. J. Pharm. Biopharm., 42(1): 16-24 (1996). |
| van Santbrink and Fauser, “Urinary follicle-stimulating hormone for normogonadotropic colomiphene-resistant anovulatory infertility: Prospective, randomized comparison between low dose step-up and step-down dose regimens,” J. Clin. Endocrin. Metab., 82(11): 3597-3602 (1997). |
| Tracy et al., “Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheresin vivo and in vitro.” Biomaterials. 20(11:): 1057-1062 (1999). |
| Ertl et al., “Poly (DL-lactide-co-glycolide) microspheres as carriers for peptide vaccines,” Vaccine 14(9):879-885.(1996). |
| Thompson et al., “Biodegradable microspheres as a delivery system for rismorelin porcine, a porcine-growth-hormone-releasing hormone,” Journal of Controlled Release 43(1):9-22 (1997). |
| “Abstracts 2007,” Diabetologia Clinical & Experimental Diabetes & Metabolism, Springer, Berlin, Germany, vol. 50 S243 (Aug. 21, 2007) (paragraph [0586]) (XP002538652). |
| Jetschmann et al., “Open-label rising-dose study of omega interferon in IFN-naive patients with chronic hepatitis C,” Gastroenterology 122:A278-A347 (Apr. 1, 2002) (Abstract M1454). |
| Bray, “Gut Signals and Energy Balance: Ghrelin, Peptide YY, Leptin, and Amylin,” (Dec. 19, 2007) (slides and transcript for presentation at Medscape CME). |
| “Implantable infusion pumps: technology poised for takeoff,” BBI Newsletter 17(12):209-211 (Dec. 1994). |
| Adamson et al., “Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer,” J. Clin. Oncol. 15(11):3330-3337 (Nov. 1997). |
| Adolf et al., “Monoclonal antibodies and enzyme immunoassays specific for human interferon (IFN) ω1: evidence that IFN-ω1 is a component of human leukocyte IFN,” Virology 175(2):410-471 (Apr. 1990). |
| Adolf et al., “Antigenic structure of human interferon ω1 (Interferon αll 1): comparison with other human interferons,” J. Gen. Virol. 68(6):1669-1676 (Jun. 1987). |
| Adolf et al., “Purification and characterization of natural human interferon ω1,” J. Bio. Chem. 265(16):9290-9295 (Jun. 1990). |
| Adolf et al., “Human interferon ω1: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein,” Biochim. Biophys. Acta 108(9):167-174 (Jun. 1991). |
| Andrx Pharmaceuticals, LLC, ANDA for Concerta® Extended-Release Tablets, 6 pages (correspondence dated Sep. 6, 2005). |
| ASTM International, Annual Book of ASTM Standards, 8.02:208-211, 584-587 (1984). |
| Ansel et al., “Dosage Form Design: Pharmaceutical and Formulation Considerations,” Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 3 at 87-92 (7th ed. Lippincott Williams & Wilkins 1999). |
| Ansel et al., “Modified-Release Dosage Forms and Drug Delivery Systems,” Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 8 at 229-243 (7th ed. Lippincott Williams & Wilkins 1999). |
| Aulitzky, “Successful Treatment of Metastatic Renal Cell Carcinoma With a Biologically Active Dose of Recombinant Interferon-Gama,” Journal of Clinical Oncology 7(12):1875-1884 (1989). |
| Hauck, “Engineer's Guide to Plastics,” Materials Engineering 5(72):38-45 (Jul. 17, 1972). |
| Bailon et al., “Rational Design of a Potent, Long-lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol-conjugated Interferon Alpha-2a for the Treatment of Hepatitis C,” Bioconjugate Chemistry 12(2):195-202 (2001). |
| Bakan et al., “Physicochemical Characterization of a Synthetic Lipid Emulsion for Hepatocyte-Selective Delivery of Lipophilic Compounds: Application to Polyiodinated triglycerides as Contrast Agents for Computed Tomography,” J. Pharm. Sci., 85(9):908-914 (1996). |
| Bakhtiar et al., “Taking Delivery,” Soap Perfumery & Cosmetics 76(3):59-65 (2003) (liposomes in cosmetic delivery systems). |
| Balkwill,F., “Interferons,” Lancet 1(8646):1060-1063 (May 1989). |
| Bauer et al., “Non-aqueous emulsions as vehicles for capsule fillings,” Drug Dev. & Industrial Pharmacy 10(5):699-712 (1984). |
| Bekkering et al., “Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model,” Hepatology 33(2):419-423 (Feb. 2001). |
| Bell et al., “Hamster preproglucagon contains the sequence of glucagon and two related peptides,” Nature 302:716-718 (1983). |
| Bell et al., “Impact of moisture on thermally induced denaturation and decomposition of lyophilized bovine somatotropin,” Drug Delivery Research & Dev. Biopolymers, (35):201-209 (1995). |
| Bertoncello et al., “Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil,” Int. J. Radiat. Biol. 67(1):57-64 (1995). |
| Bohlinder et al., “Use and characteristics of a novel lipid particle-forming matrix as a drug-carrier system,” Euro. J. Pharm. Sci. 2(4):271-279 (1994). |
| Bolinger et al., “Recombinant interferon γ for treatment of chronic granulomatous disease and other disorders,” Clin. Pharm. 11(10):834-850 (Oct. 1992). |
| Bonkovsky et al., “Outcomes research in chronic viral hepatitis C: effects of interferon therapy,” Can. J. Gastroenterol. 14(Supp. B):21B-29B (Jul.-Aug. 2000). |
| Borden et al., “Second-generation interferons for cancer: clinical targets,” Semin. Cancer Biol. 10(2):125-144 (Apr. 2000). |
| Boue et al., “Antiviral and antiluteolytic activity of recombinant bovine IFN-ω1 obtained from Pichia pastoris,” J. Interferon & Cytokine Res. 20:677-683 (2000). |
| Buckwold et al. “Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses,” Antiviral Res. 73(2):118-25 (Feb. 2007) (Epub Sep. 11, 2006). |
| Cantor, “Theory of lipid monolayers comprised of mixtures of flexible and stiff amphiphiles in anthermal solvents: fluid phase coexistence,” J. Chem. Physics 104(20):8082-8095 (1996). |
| CAS No. 56-81-5 (Nov. 16, 1984). |
| Chang et al., “Biodegradable polyester implants and suspension injection for sustained release of a cognitive enhancer,” Pharm. Tech. 20(1):80-84 (1996). |
| Chapman et al., “Physical Studies of Phospholipids. VI. Thermotropic and Lyotropic Mesomorphism of Some 1,2-Diacylphosphatidylcholines (lecithins),” Chem. & Physics of Lipids 1(5):445-475 (1967). |
| Chaumeil, “Micronization: a method of improving the bioavailability of poorly soluble drugs,” Methods & Findings in Experimental & Clinical Pharmacology 20(3):211-215 (1998). |
| Clark et al., “The diabetic Zucker fatty rat,” Proc. Soc. Exp. Biol. 173(1):68-75 (1983). |
| Condino-Neto, “Interferon-γ improves splicing efficiency of CYBB gene transcripts in an interferon responsive variant of chronic granulomatous disease due to a splice site consensus region mutation,” Blood 95(11):3548-3554 (Jun. 2000). |
| Darney, “Subdermal progestin implant contraception,” Current Opinion in Obstetrics & Gynecology 3:470-476 (1991). |
| Das et al., “Reviewing Antisense Oligonucleotide Therapy: Part 2, Delivery Issues,” BioPharm, 2(11):44-51 (1999). |
| Dash et al., “Therapeutic applications of implantable drug delivery systems,” Journal of Pharmacological and Toxicological Methods, 40(1):1-12 (1998). |
| Davis et al., “Durability of viral response to interferon alone or in combination with oral ribavirin in patients with chronic hepatitis C,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 570 ). |
| Deacon et al., “GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion,” Am. J. Physiol. Endocrinol. Metab., 282:E873-E879 (2002). |
| Desai et al., “Protein structure in the lyophilized state: a hydrogen isotope exchange/NMR study with bovine pancreatic trypsin inhibitor,” J. Am. Chem. Soc. 116(21):9420-9422 (1994). |
| Di Marco et al., “Combined treatment of relapse of chronic hepatitis C with high-dose α-2B interferon plus ribavirin for 6 or 12 months,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 569). |
| Dorr et al., “Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days,” J. Interferon Res. 8:717-725 (1988). |
| Uhlig et al., “The electro-osmotic actuation of implantable insulin micropumps,” J. Biomed. Materials Res. 17:931-943 (1983). |
| Efendic et al., “Overview of incretin hormones,” Horm. Metab. Res., 36(11-12):742-746 (2004). |
| Eissele et al., “Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide,” Life Sci., 55(8):629-634 (1994). |
| Elias et al., “Infusional Interleukin-2 and 5-fluorouracil with subcutaneous interferon-α for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study,” Cancer 89(3):597-603 (Aug. 2000). |
| Eng et al., “Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas,” J. Biol. Chem., 267(11):7402-7405 (1992). |
| Eng et al., “Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom,” J. Biol. Chem., 265(33):20259-20262 (1990). |
| Eppstein et al., “Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor,” PNAS USA 82:3688-3692 (1985). |
| Eros et al., “Multiple phase emulsions as controlled drug delivery therapeutic systems,” Proc.-Conf. Colloid Chem. 193-196 (1993). |
| Fang et al., “The impact of baseline liver histology on virologic response to interferon γ-2b±p ribavirin therapy in patients with chronic hepatitis C,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 572). |
| Felker et al., “The Rate of Transfer of Unesterified Cholesterol from Rat Erythrocytes to Emulsions Modeling Nascent Triglyceride-Rich Lipoproteins and Chylomicrons Depends on the Degree of Fluidity of the Surface,” J. Nutritional Biochem. 4(1):630-634 (1993). |
| Ferenci et al., “Combination of interferon (IFN) induction therapy and ribavirin in chronic hepatitis C,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 977). |
| Fontaine et al., “Recovery from chronic hepatitis C in long-term responders to ribarivin plus interferon α,” Lancet 356(9223):41 (Jul. 2000). |
| Franchetti et al., “Furanfurin and Thiophenfurin: Two Novel Tiazofurin Analogues. Synthesis, Structure, Antitumor Activity, and Interactions with Inosine Monophosphate Dehydrogenase,” J. Medicinal Chem. 38(19):3829-3837 (1995). |
| Fujii et al., “Effect of phosphatidylcholine on Skin Permeation of Indomethacin from gel prepared with Liquid Paraffin and Hydrogenated Phospholipid,” Int'l J. Pharmaceutics 222(1):57-64 (2001). |
| Fujii et al., “Enhancement of skin permeation of miconazole by phospholipid and dodecyl 2-(N, N-dimethylamino) propionate (DDAIP),” Int'l J. Pharmaceutics 234(1-2):121-128 (2002). |
| Luft et al., “Electro-osmotic valve for the controlled administration of drugs,” Med. & Biological Engineering & Computing 45-50 (Jan. 1978) (non-English with English abstract). |
| Gan To Kagaku Ryoho, “Phase II study of recombinant leukocyte A interferon (Ro22-8181) in malignant brain tumors,” Cancer & Chemotherapy 12(4):913-920 (Apr. 1985) (non-English with English abstract). |
| Gappa et al., “Juvenile laryngeal papillomatosis—a case report,” Pneumologie 45(11):936-938 (Nov. 1991) (XP009079028) (non-English with English abstract). |
| Gause et al., “Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer,” J. Clin. Oncol. 14(8):2234-2241 (Aug. 1996). |
| Ghiglione et al., “How glucagon-like is glucagon-like peptide-1?” Diabetologia 27:599-600 (1984). |
| Glue et al., “A dose-ranging study of Peg-intron and ribavirin in chronic hepatitis C—safety, efficacy, and virological rationale,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX(Nov. 5-9, 1999)(Abstract 571). |
| Goke et al., “Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells,” J. Biol. Chem., 268(26):19650-19655 (1993). |
| Gonzales et al., “Randomized controlled trial including an initial 4-week ‘induction’ period during one year of high-dose interferon α-2B treatment for chronic hepatitis C,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 975). |
| Gosland et al., “A phase I trial of 5-day continuous infusion cisplatin and interferon alpha,” Cancer Chemother. Pharmacol. 37(1-2):39-46 (1995). |
| Grant et al., “Combination therapy with interferon-α plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study,” J. Med. Virol. 61(4):439-442 (Aug. 2000). |
| Gutniak et al., “Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus,” N. Engl. J. Med., 326(20):1316-1322 (1992). |
| Hageman, “The Role of Moisture in Protein Stability, ” Drug Dev. & Ind. Pharm. 14(14):2047-2070 (1988). |
| Heathcote et al., “Peginterferon alfa-2a in Patients With Chronic Hepatitis C and Cirrhosis,” New England J. Med. 343(23):1673-1680 (2000). |
| Heim et al., “Intracellular signaling and antiviral effects of interferons,” Dig. Liver Dis. 32(3):257-263 (Apr. 2000). |
| Heinrich et al., “Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid,” Endocrinol., 115:2176-2181 (1984). |
| Hellstrand et al., “Histamine and cytokine therapy,” Acta Oncol. 37(4):347-353 (1998). |
| Hellstrand et al., “Histamine and the response to IFN-α in chronic hepatitis C,” Interferon Cytokine Res. 18(1):21-22 (Jan. 1998). |
| Hellstrand et al., “Histamine in immunotherapy of advanced melanoma: a pilot study,” Cancer Immunol Immunother. 39(6):416-419 (Dec. 1994). |
| Hisatomi et al., “Toxicity of polyoxyethylene hydrogenated castor oil 60 (HCO-60) in experimental animals,” J. Toxicol. Sci., 18(3):1-9 (1993). |
| Hodoshima et al., “Lipid nanoparticles for delivering antitumor drugs,” International Journal of Pharmaceutics, 146(1):81-92 (1997). |
| Hoffmann-La Roche Inc., Pegasys® (peginterferon alfa-2a), 15 pages (2002). |
| Horton et al., “Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice” Cancer Res 59(16):4064-4068 (Aug. 1999). |
| Hubel et al., “A phase I/II study of idarubicin dexamethasone and interferon-alpha (1-Dexa) in patients with relapsed or refractory multiple myeloma” Leukemia 11 Suppl 5:S47-S51 (Dec. 1997). |
| Iacobelli et al., “A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer,” Am. J. Clin. Oncol. 18(1):27-31 (1995). |
| IFNB Multiple Sclerosis Study Group, “Interferonβ-1b is effective in relapsing-remitting multiple sclerosis,” Neurology 43(4):655-667 (Apr. 1993). |
| Intermune® Inc., Infergen® (Interferon alfacon-1), 5 pages (2002). |
| “Introduction to Antibodies”, http://www.chemicon.com/resource/ANT101/a1.asp, 8 pages (retrieved May 2, 2007). |
| Isaacs et al., “Virus interference. I. The interferon,” Pro. R. Soc. Lond. B. Biol. Sci. 147:258-267 (1957). |
| Jain et al., “Controlled delivery of drugs from a novel injectable in situ formed biodegradable PLGA microsphere system,” J. Microencapsulation 17(3):343-362 (2000). |
| Jordan et al., “Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present and Future Recommendations,” The Oncologist 12(9):1143-1150 (2007). |
| Kabalnov et al., “Macroemulsion type and stability of alkane-water-phospholipid systems,” Abstracts of Papers, Part 1, 210th ACS National Meeting, 0-8412-3222-9, American Chemical Society, Chicago, IL (Aug. 20-24, 1995) (Abstract only). |
| Kabalnov et al., “Phospholipids as Emulsion Stabilizers.2. Phase Behavior Versus Emulsion Stability,” Journal of Colloid and Interface Science 184(1):227-235 (1996). |
| Khalili et al., “Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C,” Am. J. Gastroenterol. 95(5):1284-1289 (May 2000). |
| Kildsig et al., “Theoretical Justification of Reciprocal Rate Plots in Studies of Water Vapor Transmission through Films,” J. Pharma. Sci. 29(11):1634-01637 (Nov. 17, 1970). |
| Kirkwood et al., “Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684,” J. Clin. Oncol. 14(1):7-17 (1996). |
| Kita et al., “Characterization of a polyethylene glycol conjugate of recombinant human interferon-γ,” Drug Des. Deliv. 6(3):157-0167 (Sep. 1990). |
| Knepp et al., “Identification of antioxidants for prevention of peroxide-mediated oxidation of recombinant human ciliary neurotrophic factor and recombinant human nerve growth factor,” J. Pharm. Sci. Tech. 50(3):163-171 (1996). |
| Knepp et al., “Stability of nonaqueous suspension formulations of plasma derived factor IX and recombinant human alpha interferon at elevated temperatures,” Pharma. Res. 15(7):1090-1095 (1998). |
| Knobler et al., “Systemic α-interferon therapy of multiple sclerosis,” Neurology 34(10):1273-1279 (Oct. 1984). |
| Kovacevic et al., “Treatment of chronic viral hepatitis B in secondary membranoproliferative glomerulonephritis using recombinant α-2 interferon,” Maksic Dj Vojnosanit. Pregl. 57(2):235-240 (Mar.-Apr. 2000) (non-English with English abstract). |
| Kracke et al., “Mx proteins in blood leukocytes for monitoring interferon β-1b therapy in patients with MS,” Neurology 54(1):193-199 (Jan. 2000). |
| Kronenberger et al., “Influence of interferon-α on CD82-expression in HCV-positive patients,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 976). |
| Krown et al., “Interferons and interferon inducers in cancer treatment,” Semin. Oncol. 13(2):207-217 (1986). |
| Kubes et al., “Cross-species antiviral and antiproliferative activity of human interferon-ω,” J. Interferon Res. 14:57-59 (1994). |
| Kunzi et al., “Role of interferon-stimulated gene ISG-15 in the interferon-ω-mediated inhibition of human immunodeficiency virus replication,” J. Interferon Cytokine Res. 16(11):919-927 (Nov. 1996). |
| Larsson, “Stability of emulsions formed by polar lipids,” Progress in the Chemistry of Fats and Other Lipids 16:163-0169 (1978). |
| Lee et al., “Dynamics of hepatitis C virus quasispecies turnover during interferon-A treatment,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 974). |
| Lee, “Therapy of hepatitis C: interferon alfa-2A trials,” Hepatology 26: 89S-95S (Sep. 1997) (XP000981288). |
| Lopez et al., “Mammalian pancreatic preproglucagon contains three glucagon-related peptides,” Proc. Natl. Acad. Sci. USA, 80(18):5485-5489 (1983). |
| Lukaszewski et al., “Pegylated α interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on host immune response to infection,” J. Virol. 74(11):5006-5015 (Jun. 2000). |
| Lund et al., “Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem,” Proc. Natl. Acad. Sci. USA, 79(2):345-349 (1982). |
| Lundberg, “A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol),” J. Pharm. & Pharmacol. 49(1):16-21 (1997). |
| Magnuson et al. “Enhanced recovery of a secreted mammalian protein from suspension culture of genetically modified tobacco cells,” Protein Expression & Purification 7:220-228 (1996). |
| Malley et al., “Chronic Toxicity And Oncogenicity Of N-Methylpyrrolidone (Nmp) In Rats And Mice By Dietary Administration,” Drug Chem Toxicol. 24(4):315-38 (Nov. 2001). |
| Manning et al., “Stability of protein pharmaceuticals,” Pharm. Res. 6(11):903-918 (1989). |
| Marincola et al., “Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer,” J. Clinical Oncol. 13(5):1110-1122 (1995) (XP009078965). |
| Massey, “Interaction of vitamin E with saturated phospholipid bilayers,” Biochem. & Biophys. Res. Comms. 106(3):842-847 (1982). |
| McHutchison et al., “Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C,” N. Engl. J. Med. 339(21):1485-1492 (Nov. 1998). |
| McHutchison et al., “Open-label phase 1B study of hepatitis C viral dynamics with omega interferon treatment,” Hepatology 34(4):A333 (Oct. 1, 2001) (XP004716177) (Abstract Only). |
| Meier et al., “The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans,” Am. J. Physiol. Endocrinol. Metab., 290(6):E1118-E1123 (2006). |
| Merad et al., “Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-α plus IL-2 and IL-12),” J. Immunother. 23(3):369-378 (May-Jun. 2000). |
| Milella et al., “Neutralizing antibodies to recombinant α-interferon and response to therapy in chronic hepatitis C virus infection,” Liver 13(3):146-150 (Jun. 1993). |
| Mohler, “Primer on electrodeposited coatings,” Materials Engineering 5:38-45 (1972). |
| Mojsov, “Structural requirements for biological activity of glucagon-like peptide-I,” Int. J. Peptide Protein Research, 40:333-343 (1992). |
| Morgan, “Structure and Moisture Permeability of Film-Forming Poloyers,” Ind. Eng. Chem. 45(10):2296-2306 (1953). |
| Motzer et al., “Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma,” J. Clinical Oncol. 19(5):1312-1319 (2001). |
| Nauck et al., “Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients,” Diabet. Med., 15(11):937-945(1998). |
| Neumann et al., “Hepatitis C Viral Dynamics In Vivo and the Antiviral Efficacy of Interferon-alpha Therapy,” Science 282:103-107 (Dec. 1998). |
| Nieforth et al., “Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon-α-2a and a polyethylene glycol-modified derivative in healthy subjects,” Clin. Pharmacol. Ther. 59(6):636-646 (Jun. 1996). |
| Norden et al., “Physicochemical characterization of a drug-containing phospholipid-stabilized o / w emulsion for intravenous administration,” Eur. J. Pharm. Sci. 13(4):393-401 (2001). |
| Olaso et al., “Early prediction of lack of response to treatment with interferon and interferon plus ribavirin using biochemical and virological criteria in patients with chronic hepatitis C,” Esp. Quimioter. 12(3):220-228 (Sep. 1999) (non-English with English abstract). |
| Ortiz et al., “A differential scanning calorimetry study of the interaction of α-tocopherol with mixtures of phospholipids,” Biochim et Biophys Acta 898(2):214-222 (1987). |
| Panitch, “Interferons in multiple sclerosis,” Drugs 44(6):946-962 (Dec. 1992). |
| Patzelt et al., “Identification and processing of proglucagon in pancreatic islets,” Nature, 282:260-266 (1979). |
| Peterson et al., “Zucker Diabetic Fatty Rat as a Model for Non-insulin-dependent Diabetes Mellitus,” ILAR Journal, 32(3):16-19 (1990). |
| Peterson et al., “Neuropathic complications in the Zucker diabetic fatty rat (ZDF/Drt-fa),” Frontiers in diabetes research. Lessons from Animal Diabetes III, Shafrir, E. (ed.), pp. 456-458, Smith-Gordon, London (1990). |
| Pimstone et al., “High dose (780 MIU/52 weeks) interferon monotherapy is highly effective treatment for hepatitis C,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24-2000) (Abstract 973). |
| Plauth et al., “Open-label phase II study of omega interferon in previously untreated HCV infected patients,” Hepatology 34(4):A331 (Oct. 1, 2001) (XP004716169) (Abstract Only). |
| Plauth et al., “Open-label study of omega interferon in previously untreated HCV-infected patients,” J. Hepatology 36(Supp. 1):125 (Apr. 2002) (XP002511882) (Abstract Only). |
| Pohl et al., “Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues,” J. Biol. Chem., 273(16):9778-9784 (1998). |
| Poynard et al., “Is an ‘a la carte’ combined interferon α 2b plus ribavirin possible for the first line treatment in patients with chronic hepatitis C,” Hepatology 31(1):211-218 (Jan. 2000). |
| Poynard et al., “Randomized trial of interferon α 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α 2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis C virus,” Lancet 352(9138):1426-1432 (Oct. 1998). |
| “Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD,” Intarcia Therapeutics, Inc. (Sep. 22, 2010) (Press Release). |
| Quesada et al., “Interferons in Hematological Malignancies”, eds. Baron et al., U. Tex. 487-495 (1987). |
| Quintanar-Guerrero et al., “Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides,” Pharm. Res. 14(2):119-127 (1997). |
| Rajkumar et al., “Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma,” Int'l J. Radiat. Oncol. Biol. Phys. 40(2):297-302 (Jan. 15, 1998). |
| Roche Pharmaceuticals, Roferon®—A (Interferon alfa-2a, recombinant), 22 pages (2003). |
| Roff et al., “Handbook of Common Polymers”, Cleveland Rubber Co. 72 pages (1971). |
| Rogers et al., “Permeability Valves,” Ind. & Eng. Chem. 49(11):1933-1936 (Nov. 17, 1957). |
| Roman et al., “Cholestasis in the rat by means of intravenous administration of cyclosporine vehicle, Cremophor EL,” Transplantation 48(4):554-558 (1989). |
| Roth et al., “High Dose Etretinate and Interferon-alpha—A Phase I Study in Squamous Cell Carcinomas and Transitional Cell Carcinomas,” Acta Oncol. 38(5):613-617 (1999). |
| Roth et al., “Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity,” Endocrinol. 148(12):6054-61 (Dec. 2007). |
| Schepp et al., “Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2,” Eur. J. Pharmacol., 269(2):183-191 (1994). |
| Schering Corp., Intron® A for Injection, 6 pages (2001). |
| Schering Corp., PEG-Intron™ (Peginterferon alfa-2b) Powder for Injection, 29 pages (2003). |
| Schmalfub et al., “Modification of drug penetration into human skin using microemulsions,” J. Controlled Release 46(3):279-285 (1997). |
| Sen et al., “The interferon system: a bird's eye view of its biochemistry,” J. Biol. Chem. 267(8):5017-5020 (Mar. 1992). |
| Shiffman et al., “A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999) (Abstract 567). |
| Shima et al., “Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment,” J. Gastroenterol. Hepatol. 15(3):294-299 (Mar. 2000). |
| Shiratori et al., “Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy,” Ann. Int. Med. 132(7):517-524 (Apr. 2000). |
| Simon et al., “A longitudinal study of T1 hypointense lesions in relapsing Ms: MSCRG trial of interferon β1a,” Neurology 55(2):185-192 (Jul. 2000). |
| Sparks et al., “Lipoprotein alterations in 10- and 20-week-old Zucker diabetic fatty rats: hyperinsulinemic versus insulinopenic hyperglycemia,” Metabolism, 47(11):1315-1324 (1998). |
| Sulkowski et al., “Pegylated Interferon Alfa-2A (Pegasys™) and Ribavirin Combination Therapy for Chronic Hepatitis C: A Phase II Open-Label Study,” Gastroenterology 118(4, Supp. 2) (2000) (Abstract 236). |
| Sulkowski et al., “Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study,” Biodrugs 16(2):105-109 (2002). |
| Talpaz et al., “Phase I study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia,” Blood 98(6):1708-1713 (2001). |
| Talsania et al., “Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice,” Endocrinology 146(9):3748-56 (Sep. 2005). |
| Tanaka et al., “Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients,” Int. J. Cancer 87(5):741-749 (Sep. 2000). |
| Tong et al., “Prediction of response during interferon α 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison,” Hepatology 26(6):1640-01645 (Dec. 1997). |
| Touza Rey et al., “The clinical response to interferon-γ in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus,” Ann. Med. Int. 17(2):86-87 (Feb. 2000). |
| Trudeau et al., “A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer,” Cancer Chemother. Pharmacol. 35(6):496-500 (1995). |
| Tseng et al., “Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat,” PNAS USA, 90(5):1992-1996 (1993). |
| Tsung et al., “Preparation and Stabilization of Heparin/Gelatin Complex Coacervate Microcapsules,” J. Pharm. Sci. 86(5):603-7 (May 1997). |
| Unniappan et al., “Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY,” Diabetologia; Clinical and Experimental Diabetes and Metabolism 49(8):1915-1923 (Jun. 27, 2006). |
| Vokes et al., “A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest,” Cancer Chemother. Pharmacol. 35(4):304-312 (1995). |
| Vrabec, “Tympanic membrane perforations in the diabetic rat: a model of impaired wound healing,” Otolaryngol. Head Neck Surg., 118(3 Pt. 1):304-308 (1998). |
| Wang et al., “Preferential interaction of α-tocopherol with phosphatidylcholines in mixed aqueous dispersions of phosphatidylcholine and phosphatidylethanolamine,” Eur. J. Biochem. 267(21):6362-6368 (2000). |
| Wang et al., “Ripple phases induced by α-tocopherol in saturated diacylphosphatidylcholines,” Archives of Biochem. & Biophys. 377(2):304-314 (2000). |
| Wang et al., “The distribution of α-tocopherol in mixed aqueous dispersions of phosphatidylcholine and phosphattidylethanolamine,” Biochimica et Biophysica Acta-Biomembranes 1509(1-2):361-372 (2000). |
| Wang et al., “Parenteral formulations of proteins and peptides: stability and stabilizers,” J. Parenter. Sci. Technol. 42(2S):S4-S26 (1988). |
| Weinstock-Guttman et al., “What is new in the treatment of multiple sclerosis?” Drugs 59(3):401-410 (Mar. 2000). |
| Weissmann et al., “The interferon genes,” Prog. Nucleic Acid Res. Mol. Biol. 33:251-300 (1986). |
| Wright et al., “Preliminary experience with α-2b-interferon therapy of viral hepatitis in liver allograft recipients,” Transplantation 53(1):121-123 (Jan. 1992). |
| Young et al., “Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta),” Diabetes, 48(5):1026-1034 (1999). |
| Younossi et al., “The role of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with α interferons, in the treatment of chronic hepatitis C,” Semin. Liver Dis. 19(Supp. 1):95-102 (1999). |
| Yu et al., “Preparation, characterization, and in vivo evaluation of an oil suspension of a bovine growth hormone releasing factor analog,” J. Pharm. Sci. 85(4):396-401 (1996). |
| Zeidner et al., “Treatment of FeLV-induced immunodeficiency syndrome (feLV-FAIDS) with controlled release capsular implantation of 2′,3′-dideoxycytidine,” Antivir. Res. 11(3):147-0160 (Apr. 1989). |
| Zein, “Interferons in the management of viral hepatitis,” Cytokines Cell Mol. Ther. 4(4):229-241 (Dec. 1998). |
| Zeuzem et al., “Peginterferon Alfa-2a in Patients with Chronic Hepatitis C,” New Engl. J. Med. 343(23):1666-1672 (2000). |
| Zeuzem et al., “Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon α on viral turnover,” Hepatology 28(1):245-252 (Jul. 1998). |
| Zhang et al., “Report on Large Dosage Interferon to Treat 30 Cases of Viral Encephalitis,” J. Clinical Pediatrics 14(2):83-84 (1996). |
| Zhang et al., “A new strategy for enhancing the stability of lyophilized protein: the effect of the reconstitution medium on keratinocyte growth factor,” Pharm. Res. 12(10):1447-1452 (1995). |
| Zheng et al. “Therapeutic Effect of Interferon Varied Dose in Treating Virus Encephalitis,” Beijing Med. J. 13(2):80-81 (1998). |
| Ziesche et al., “A preliminary study of long-term treatment with interferon γ-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis,” New Engl. J. Med. 341(17):1264-1269 (Oct. 1999). |
| Sanofi-Aventis U.S. LLC, Prescribing Information for Adlyxin® (Lixisenatide) Injection, for Subcutaneous Use, rev. Jul. 2016, 31 pages. |
| Amylin Pharmaceuticals, Inc., Prescribing Information for Byetta® (Exenatide) Injection, rev. Oct. 2009, 34 pages. |
| Astrazeneca Pharmaceuticals LP, Prescribing Information for Bydureon® (Exenatide Extended-Release for Injectable Suspension), rev. Mar. 2015, 60 pages. |
| Novo Nordisk A/S, Prescribing Information for Victoza® (Liraglutide [rDNA Origin] Injection), Solution for Subcutaneous Use, v. 1, Jan. 2010, 23 pages. |
| Glaxosmithkline LLC, Prescribing Information for Tanzeum® (Albiglutide) for Injection, for Subcutaneous Use, rev. Jun. 2014, 55 pages. |
| Eli Lilly & Company, Prescribing Information for Trulicity® (Dulaglutide) Injection, for Subcutaneous Use, rev. Mar. 2015, 19 pages. |
| Adolf, “Human interferon omega—a review,” Mult. Sclr. 1:S44-47 (1995). |
| Costantino et al., “Protein Spray Freeze Drying. 2. Effect of Formulation Variables on particle Size and Stability,” J. Pharm. Sci. 91:388-395 (2002). |
| Henry et al., “Comparing ITCA 650, continuous subcutaneous delivery of exenatide via DUROS® device, vs. twice daily exenatide injections in metformin-treated type 2 diabetes,” oral presentation at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden , 21 pages (Sep. 20-24, 2010). |
| Huggins et al., “Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses,” Antimicrobial Agents & Chemotherapy, 26(4):476-480 (1984). |
| Ishiwata et al., “Clinical effects of the recombinant feline interferon-omega on experimental parvovirus infection in beagle dogs,” J. Vet. Med. Sci. 60(8):911-917 (1998). |
| Johnson et al., “How interferons fight disease,” Sci. Am. 270(5):68-75 (May 1994). |
| Lublin et al., “Defining the clinical course of multiple sclerosis: results of an international survey,” Neurology, 46:907-911 (1996). |
| Madsbad, “Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)—preclinical and clinical results,” Best Practice & Research Clinical Endocrinology & Metabolism 23:463-77 (2009). |
| Nielsen, “Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes,” Drug Discovery Today 10(10):703-710 (May 15, 2005). |
| Palmeri et al., “5-Fluorouracil and recombinant a-interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study,” J. Chemotherapy 2(5):327-330 (Oct. 1990). |
| Patti et al., “Natural interferon-b treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients: two-year study,” Acta. Neurol. Scand. 100:283-289 (1999). |
| Paty et al., “Interferon beta-1 b is effective in relapsing-remitting multiple sclerosis,” Neurology 43:662-667 (1993). |
| PCT International Search Report for PCT/US2009/00+D15360916, 4 pages (dated Aug. 12, 2009). |
| “Intarcia Therapeutics Announces Final Results from a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1,” NLV Partners Press Coverage Portfolio News (Apr. 12, 2007) (Press Release). |
| Quianzon et al., “Lixisenatide-Once-daily Glucagon-like Peptide-1 Diabetes,” US Endocrinology 7(2):104-109 (2011). |
| Ratner et al., “Dose-dependent effects of the one-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metfmmin: a randomized, double-blind, placebo-controlled trial,” Diabetic Medicine 27(9):1024-1032 (Sep. 2010). |
| Roberts et al., “The Evolution of the Type I Interferons1,” J. Interferon Cytokine Res. 18(10):805-816 (Oct. 1998). |
| Rohloff et al., “DUROS Technology Delivers Peptides and Proteins at Consistent Rate Continuously for 3 to 12 Months,” J. Diabetes Sci. & Tech., 2(3):461-467 (May 1, 2008). |
| “Sequence Listings for International Patent Application Publication No. W02009109927, WIPO Patentscope”, http://patentscope.wipo.int/search/docservicepdf_pct/id00000008776887, 1 page (last visited Nov. 14, 2012). |
| Shire et al., “Challenges in the Development of High Protein Concentration Formulations,” J. Pharm. Sci. 93:1390-1402 (2004). |
| Smith, “Peripheral Neuro-hormones as a Strategy to Treat Obesity,” oral presentation at the 2007 Cardiometabolic Health Congress in Boston, MA, pp. 1-35 (Sep. 26-29, 2007). |
| Written Opinion for International Patent Application No. PCT/US2009/005629 (corresponding to U.S. Appl. No. 12/587,946), 5 pages (dated Apr. 15, 2011). |
| Zhang et al., “Efficacy observations of different dosages of interferon to treat 150 Hepatitis B carriers,” Current Physician 2(12):45-46 (1997). |
| Pratley et al., “Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors,” Rev. Diabet. Stud., 5(2):73-94 (2008). |
| Gonzalez, et al., “Hemoglobin Alc: A Reliable and Accurate Test for Diabetes Care? A Prospective Study in Mexico,” Salud Publica Mex 55:462-468 (2013). |
| Ahn et al., “A New Approach to Search for the Bioactive Confirmation of Glucagon: Positional Cyclization Scanning” Journal of Medicinal Chemistry, vol. 44, No. 19, (2001): 3109-3116. |
| Number | Date | Country | |
|---|---|---|---|
| 20200054717 A1 | Feb 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61072202 | Mar 2008 | US | |
| 60926005 | Apr 2007 | US | |
| 60650225 | Feb 2005 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12148896 | Apr 2008 | US |
| Child | 12927432 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15612581 | Jun 2017 | US |
| Child | 16441803 | US | |
| Parent | 15291523 | Oct 2016 | US |
| Child | 15612581 | US | |
| Parent | 14605348 | Jan 2015 | US |
| Child | 15291523 | US | |
| Parent | 12927432 | Nov 2010 | US |
| Child | 14605348 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 11347562 | Feb 2006 | US |
| Child | 12148896 | US |
